Page last updated: 2024-08-21

quinazolines and Disease Exacerbation

quinazolines has been researched along with Disease Exacerbation in 505 studies

Research

Studies (505)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	6 (1.19)	18.2507
2000's	185 (36.63)	29.6817
2010's	299 (59.21)	24.3611
2020's	15 (2.97)	2.80

Authors

Authors	Studies
Chen, SY; Chu, PY; Hou, MF; Lin, CS; Lin, HY; Wu, HJ	1
Bachelot, T; Bailleux, C; Darlix, A; Jacot, W	1
Bardet, S; Brose, MS; Capdevila, J; Elisei, R; Führer, D; Gao, M; Hadoux, J; Hoff, AO; Hu, MI; Isaev, P; Jarzab, B; Keam, B; Kopeckova, K; Lin, B; Lin, Y; Maeda, P; Robinson, BG; Sherman, EJ; Singh, R; Soldatenkova, V; Tahara, M; Wadsley, J; Wirth, LJ; Wright, J	1
Cui, Y; Dai, M; Hu, Y; Kong, W; Wang, X; Wu, H; Wu, J; Yu, B; Yu, X; Zhang, H; Zheng, Y	1
Fang, MY; Fang, Y; Lei, L; Li, JL; Lv, TF; Song, Y; Wang, H; Wang, LP; Wang, WX; Wang, XJ; Xu, CW; Zhang, YB; Zhu, YC; Zhuang, W	2
Aul, R; Hill, M; Howlett, S; Pinato, DJ	1
Li, J; Peng, Z; Shen, L; Wang, Q; Wang, X; Zhang, Q	1
Chen, J; Li, X; Liu, H; Liu, M; Zhang, H	1
Bai, L; Bai, R; Chen, N; Cui, J; Han, F; Li, J; Li, W; Qian, L; Yu, Y; Zhao, Y	1
Ikeda, Y; Ikeuchi, M; Nakayama, Y; Saito, Y; Yamagishi, A; Yuki, R	1
Abramson, V; An, X; Anders, C; Bachelot, T; Bedard, PL; Borges, V; Cameron, D; Carey, L; Chien, AJ; Conlin, A; Curigliano, G; DiGiovanna, MP; Gelmon, K; Hamilton, E; Hurvitz, S; Lin, NU; Loi, S; Loibl, S; Mayor, J; McGoldrick, S; Mueller, V; Murthy, RK; O'Regan, R; Okines, A; Oliveira, M; Paplomata, E; Wardley, A; Winer, EP; Zelnak, A	1
Bastholt, L; Colzani, R; Elisei, R; Foster, M; Haddad, R; Hauch, O; Jarząb, B; Kreissl, MC; Robinson, B; Schlumberger, M; Weiss, R	1
Fujii, T; Hamamoto, R; Honjoh, H; Inoue, F; Kaneko, S; Kashiyama, T; Kojima, M; Komatsu, M; Kukita, A; Miyamoto, Y; Mori-Uchino, M; Osuga, Y; Sone, K; Taguchi, A; Takahashi, Y; Tanikawa, M; Tsuruga, T; Wada, M; Wada-Hiraike, O	1
Jaźwiec, B; Kuliszkiewicz-Janus, M; Kwiatkowski, J; Małecki, R; Rymer, W	1
Bottiglieri, A; Brambilla, M; de Braud, F; De Toma, A; Ferrara, R; Galli, G; Gallucci, R; Ganzinelli, M; Garassino, MC; Greco, GF; Labianca, A; Lo Russo, G; Lobefaro, R; Manglaviti, S; Nichetti, F; Occhipinti, M; Prelaj, A; Proto, C; Signorelli, D; Torri, V; Viscardi, G; Zilembo, N	1
Berghmans, T; Besse, B; De Maio, E; Dziadziuszko, R; Hasan, B; Menis, J; Novello, S; Peric, A; Reck, M; Remon, J; Wasag, B	1
Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X	1
Davies, L; Fukuoka, M; Gebski, V; Gralla, RJ; Inoue, A; Lee, CK; Lord, S; Marschner, I; Mitsudomi, T; Mok, T; Nakagawa, K; Rosell, R; Thongprasert, S; Tu, YK; Wu, YL; Yang, JC; Zhou, C	1
He, H; He, X; Lan, BH; Li, MX; Li, RQ; Liu, GD; Ruan, ZH; Wang, G; Wu, Y; Xiao, HL; Yang, ZZ; Zhang, ZM; Zhu, B; Zhu, YX	1
Edwards, A; Glass, JO; Li, Y; Patay, Z; Reddick, WE; Svolos, P; Sykes, A	1
Chen, JS; Chen, KY; Chih-Hsin Yang, J; Ho, CC; Liao, WY; Lin, CC; Lin, ZZ; Shih, JY; Yao, ZH; Yu, CJ	1
Hida, T; Horio, Y; Inaba, Y; Kuroda, H; Oya, Y; Sakao, Y; Shimizu, J; Yatabe, Y; Yoshida, T	1
Bosch-Barrera, J; Costa, EC; Insa, A; Isla, D; Kraemer, S; Lee, C; Majem, M; Moran, T; Palmero, R; Provencio, M; Puig, M; Reguart, N; Rosell, R; Schnell, D	1
Bobos, M; Christodoulou, C; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeras, KT; Karavasilis, V; Kouvatseas, G; Papadopoulos, G; Papandreou, CN; Rallis, G; Razis, E; Samantas, E; Syrigos, KN; Varaki, K	1
Corrao, G; Facchinetti, F; Ganzinelli, M; Garassino, MC; Lo Russo, G; Minari, R; Proto, C; Tiseo, M	1
Cui, Y; Flamini, V; Jiang, WG	1
Chen, X; Chen, Z; Kong, R; Li, Y; Lu, D; Niu, K; Sun, J; Wang, Y; Xia, L	1
Guo, R; Jin, S; Min, H; Shu, Y; Wen, W; Wu, H; Xu, T; Zhang, Z	1
Groen, HJM; Heideman, DAM; Hiltermann, TJN; Kok, K; Kuiper, JL; Saber, A; Schuuring, E; Smit, EF; Terpstra, MM; Thunnissen, E; Timens, W; van den Berg, A; van der Wekken, AJ; Wei, J	1
Jiang, Q; Jin, Y; Xin, T	1
Camidge, DR; Chand, VK; Fan, J; Freiwald, M; Gettinger, S; Groen, HJM; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Smit, EF; Wang, B	1
Akshintala, S; Balis, FM; Derse-Anthony, C; Dombi, E; Fox, E; Glod, JW; Kapustina, O; Kraft, IL; Lei, H; Lodish, M; Meltzer, PS; Merino, MJ; Shern, JF; Steinberg, SM; Waguespack, SG; Widemann, BC; Zhu, Y	1
Bagheri, N; Kosari, S; Madden, R; Peterson, GM; Thomas, J	1
Cappuzzo, F; Cseh, A; Forman, ND; Hilbe, W; Hochmair, M; Jazieh, AR; Lam, KC; Linden, S; Lorence, RM; Schuler, M; Soo, R; Stehle, G; Tsai, CM	1
Lu, H; Xie, Z; Xu, Y	1
Goto, Y; Hasegawa, Y; Hosomi, Y; Inoue, A; Isobe, H; Kaburagi, T; Kato, T; Kim, YH; Kunitoh, H; Minato, K; Mori, Y; Nishio, M; Ohashi, Y; Sakai, H; Tanai, C; Tomizawa, Y; Yamada, K; Yoh, K	1
Andreou, M; Bermudez-Brito, M; de Bree, E; Goulielmaki, E; Makrigiannakis, A; Papakonstanti, EA; Tsentelierou, E; Tzardi, M; Tzenaki, N	1
Hagiwara, K; Kondoh, Y; Lasky, JA; Saito, S	1
Almeida, VH; Berzoti-Coelho, MG; Borges, CS; Cacemiro, MDC; Castro, FA; Ferreira, AF; Figueiredo-Pontes, LL; Gomes, FG; Monteiro, RQ; Nunes, NS; Simões, BP	1
Cao, H; Ding, W; Li, C; Li, W; Liu, R; Lu, L; Shao, G; Song, J; Wang, J; Xiang, H; Yang, J; Yang, Z	1
Chen, H; Ju, X; Song, Z; Wang, Y; Wu, W; Yan, T; Yang, X; Zhang, Z	1
Begna, KH; Christopher Hook, C; Elliott, MA; Gangat, N; Hanson, CA; Ketterling, RP; Pardanani, A; Patnaik, MM; Szuber, N; Tefferi, A; Vallapureddy, RR; Wolanskyj, AP	1
Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH	1
Lang, L; Teng, Y	1
Carty, K; Davidson, S; Dive, C; Jayson, GC; McCartney, E; Paul, J; Rai, D; Simpson, K; Symonds, P; Taylor, S; Tugwood, J; West, C; Zhou, C	1
Bertran-Alamillo, J; Burbridge, M; Cantero, F; Cardona, AF; Castellví, J; Cattan, V; Codony-Servat, C; Codony-Servat, J; García-Román, S; Giménez-Capitán, A; Karachaliou, N; Molina-Vila, MA; Rodríguez, S; Roman, R; Rosell, R; Schoumacher, M; Teixidó, C; Viteri, S	1
Fujita, S; Hashimoto, A; Hashimoto, Y; Hotta, M; Ishii, K; Ito, T; Kondo, T; Konishi, A; Nakanishi, T; Nakaya, A; Nomura, S; Omura, H; Satake, A; Shinzato, I; Tanaka, T; Tanaka, Y; Yoshimura, H	1
Jin, B; Liu, J; Liu, Y; Qu, X; Su, H	1
Broniscer, A; Hillenbrand, CM; Kocak, M; Loeffler, RB; Sedlacik, J; Winchell, A	1
Juhász, E; Kim, JH; Klingelschmitt, G; Walzer, S	1
Alvarez-Larrán, A; Besses, C; Cervantes, F	1
Acharyya, S; Chakraborty, A; Dasgupta, P; Gangopadhyay, S; Sau, S	1
Chu, DT; Fukuoka, M; Mok, TS; Rukazenkov, Y; Saijo, N; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ	1
Belaid, I; Ben Ayed, F; Debbiche, G; Jlassi, H; Rais, H	1
Al-Lazikani, B; Box, C; Box, GM; Brandon, Ade H; Eccles, SA; Gowan, S; Harrington, KJ; Mendiola, M; Rogers, SJ; Valenti, M; Wilkins, A	1
Durante, C; Filetti, S; Paciaroni, A; Plasmati, K; Trulli, F	1
Chachoua, A; Desai, AM; Garcia-Reglero, V; Marquez-Medina, D; Martin-Marco, A; Muggia, F; Salud-Salvia, A	1
Chen, M; Dominguez, SL; Eastham-Anderson, J; Le Pichon, CE; Lewin-Koh, N; Ngu, H; Scearce-Levie, K; Solanoy, H; Watts, R	1
Agelaki, S; Agelidou, M; Christofillakis, C; Georgoulias, V; Giassas, S; Karampeazis, A; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Rapti, A; Samonis, G; Souglakos, J; Vamvakas, L; Voutsina, A	1
Charbonnel, B; Dejager, S; Schweizer, A	1
Hsu, JH; Li, MF; Shiau, EL; Wu, MT	1
Batchelor, TT; de Groot, J; Reardon, DA	1
Chen, MJ; Li, LY; Wang, MZ; Zhang, L; Zhao, J; Zhong, W	1
Aoudjehane, L; Clapéron, A; Conti, F; Desbois-Mouthon, C; Firrincieli, D; Fouassier, L; Ho-Bouldoires, TH; Housset, C; Merabtene, F; Mergey, M; Prignon, A; Scatton, O; Wendum, D	1
Cardarella, S; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Rabin, MS; Ramaiya, NH	1
Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N	1
Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, Y; Yun, T	1
He, C; Li, Y; Liu, M; Xu, J; Xu, Y; Zheng, L	1
Altug, S; Digumarti, R; Han, B; Kim, HK; Kim, SW; Lee, DH; Lee, JS; Orlando, M; Rodrigues-Pereira, J; Sahoo, TP; Song, XQ; Wang, J; Wang, X	1
Bichsel, KJ; Forney, E; Gogia, N; Hammiller, B; Hansen, LA; Malouff, T; Pena, Z; Watson, P	1
Bria, E; Cognetti, F; Gamucci, T; Gelibter, A; Mansueto, G; Milella, M; Moscetti, L; Ruggeri, EM; Sperduti, I; Vaccaro, V	1
Postel-Vinay, S; Schlumberger, M; Soria, JC	1
Cao, L; Freeman, JW; Hill, P; Nawrocki, ST; Peterson, L; Venkatasubbarao, K; Zhao, S; Zhou, Q	1
Korovina, IaV; Nasyrov, AR; Pirtskhalava, TL	1
Fu, R; Yang, R; Zhang, L	1
Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, W; Hurwitz, SJ; Khuri, FR; Kono, SA; Lewis, M; Moore, CE; Moreno-Williams, R; Müller, S; Nannapaneni, S; Owonikoko, TK; Ramalingam, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Yang, CS; Zhao, Y	1
Dharmarajan, S; Dinavahi, SS; Nyayapathy, S; Perumal, Y; Viswanadha, S	1
Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B	1
Baudrin, L; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Herman, D; Lavolé, A; Mennecier, B; Milleron, B; Molinier, O; Moreau, L; Morin, F; Moro-Sibilot, D; Pichon, E; Poudenx, M; Quoix, E; Sennelart, H; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G	1
Chang, C; Chen, CC; Chuang, WM; Hsieh, TF; Hung, XF; Lin, MH; Ma, WL; Shyr, CR; Tsai, YR; Zhang, C; Zhang, Q	1
Becker, MA; Farzan, T; Haluska, P; Harrington, SC; Hou, X; Kalli, KR; Krempski, JW; Weroha, SJ; Wong, TW	1
Goss, GD; Hirsh, V; Laurie, SA; Leighl, NB; Nicholas, G; Oza, A; Philip, L; Reaume, MN; Schwock, J; Shepherd, FA; Tsao, MS; Wang, L; Wright, JJ	1
Akinaga, S; Fujisaka, Y; Hayashi, H; Hirashima, T; Miyoshi, K; Murakami, H; Nakagawa, K; Satouchi, M; Takahashi, T; Takeda, K; Yamamoto, N	1
Dobrowsky, RT; Pan, P	1
Alfieri, RR; Ardizzoni, A; Bartolotti, M; Bordonaro, R; Bortesi, B; Bruzzi, P; Caffarra, C; Cavazzoni, A; Cosentino, S; Fumarola, C; Ippolito, M; Latteri, F; Petronini, PG; Ruffini, L; Scarlattei, M; Soto Parra, HJ; Spadaro, P; Tiseo, M	1
Ciuleanu, T; Cobo, M; Douillard, JY; McCormack, R; Milenkova, T; Ostoros, G; Webster, A	1
Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY	1
Bass, SA; Gibson, AM; Khurana Hershey, GK; Xiao, C; Zhang, Z	1
Baio, G	1
Afonso-Afonso, FJ; Alonso-Jáudenes, G; Amenedo, M; Barón-Duarte, FJ; Campos-Balea, B; Casal Rubio, J; Fírvida-Pérez, JL; Huidobro, G; Lázaro-Quintela, M; López-Vázquez, MD; Santomé, L; Vázquez, S	1
Arnold, AM; Boyer, MJ; Bradbury, PA; Chen, EX; Clingan, P; Ding, K; Ellis, PM; Fenton, D; Goss, GD; Hirsh, V; Laberge, F; Laurie, SA; Lee, CW; Montenegro, A; Seymour, L; Shepherd, FA; Solomon, BJ; Stockler, MR; Zukin, M	1
Egawa, C; Kagawa, Y; Kato, T; Katsura, Y; Nakahira, S; Okishiro, M; Sakisaka, H; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H	1
Antoine, M; Cadranel, J; Duruisseaux, M; Lacave, R; Lavole, A; Leprieur, EG; Rabbe, N; Rozensztajn, N; Ruppert, AM; Vieira, T; Wislez, M	1
Bellezza, G; Bennati, C; Chiari, R; Crinò, L; Duranti, S; Ludovini, V; Minotti, V; Pireddu, A	1
Eroglu, Z; Somlo, G; Tagawa, T	1
Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Kim, M; Lee, KY; Li, W; Lu, S; Massey, D; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C	1
Boers-Sonderen, MJ; Mulder, SF; Punt, CJ; van der Heijden, HF; van Herpen, CM; Vissers, KC	1
Şendur, MA; Uncu, D; Zengin, N	1
Heideman, DA; Kuiper, JL; Postmus, PE; Smit, EF; Thunnissen, E; van Wijk, AW	1
Carcereny, E; Cardenal, F; Cardona, AF; De Castro, J; Insa, A; Isla, D; Majem, M; Molina, MA; Moran, T; Pallarès, MC; Palmero, R; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Taron, M	1
Bardeesy, N; Caravan, P; Chen, X; Crenshaw, A; DePeralta, DK; Fuchs, BC; Fujii, T; Golub, TR; Gupta, S; Hoshida, Y; Kuroda, T; Lanuti, M; Lauwers, GY; McGinn, CM; Onofrio, R; Schmitt, AD; Tanabe, KK; Taylor, B; Wei, L; Winckler, W; Yamada, S	1
Beal, K; Chan, TA; Gerber, NK; Riely, GJ; Rimner, A; Shi, W; Wu, AJ; Yamada, Y; Yu, HA; Zhang, Z	1
Chen, X; Fan, L; Fei, K; Gao, G; He, Y; Li, A; Li, J; Li, S; Li, W; Li, X; Ren, S; Schmid-Bindert, G; Shi, J; Zhao, C; Zhou, C	1
Iwase, T; Kishimoto, Y; Mori, H; Yano, T	1
Harris, RC; Paueksakon, P; Wang, Y; Zhang, MZ	1
Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S	1
Diaz-Hernandez, M; Engel, T; Henshall, DC; Hessel, EV; Jimenez-Pacheco, A; Mesuret, G; Miras-Portugal, MT; Sanz-Rodriguez, A	1
Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A	1
Dong, JZ; Lu, MQ; Wang, LP; Zhang, SN; Zou, ZL	1
Fuchs, BC; Hoshida, Y; Tanabe, KK	1
Garzon, F; Geater, SL; Gopalakrishna, P; Iannotti, N; Lee, V; Lim, WT; Mok, TS; Reyderman, L; Reynolds, C; Smith, D; Spira, A; Thongprasert, S; Wang, B; Xu, L	1
Fore, M; Mennecier, B; Prim, N	1
Ardizzoni, A; Cappuzzo, F; Cortinovis, D; de Marinis, F; Fontanini, G; Galetta, D; Gridelli, C; Grossi, F; Iurlaro, M; Lorusso, V; Novello, S; Santo, A	1
Baty, F; Betticher, DC; Brauchli, P; Brutsche, M; Droege, C; Früh, M; Gautschi, O; Joerger, M; Klingbiel, D; Ochsenbein, A; Pless, M; Rothschild, S; Stahel, RA; von Moos, R; Zappa, F	1
Li, QX; Lu, X; Wu, HL; Yang, M; Yu, SY; Yuan, XL; Zhang, L	1
Abbas, H; Blazeby, JM; Chatterjee, A; Dahle-Smith, A; Davoudianfar, M; Dutton, SJ; Falk, S; Ferry, DR; Fyfe, DW; Gamble, T; Garcia-Alonso, A; Harrison, M; Hubner, RA; Jankowski, J; Julier, P; Kerr, R; Mansoor, W; Peachey, L; Pearson, SR; Petty, RD; Thompson, J	1
Adjei, AA; Foster, NR; Grainger, AV; Marks, R; Molina, JR; Nelson, GD; Reungwetwattana, T; Steen, PD; Stella, PJ; Wright, J	1
Cohen, EE; Haddad, RI; Licitra, LF; Machiels, JP; Tahara, M	1
Balázs, G; Kovalszky, I; Losonczy, G; Moldvay, J; Pápay, J; Puskás, R	1
Meldgaard, P; Nissen, PH; Sorensen, BS; Weber, B; Winther Larsen, A	1
Ando, M; Hasegawa, Y; Kimura, T; Kojima, E; Nomura, F; Ogasawara, T; Saito, H; Shindoh, J; Sugino, Y; Suzuki, R; Takahashi, K; Yamamoto, M; Yoshida, N	1
Bevilacqua, S; D'Alessio, A; De Luca, A; Frezzetti, D; Gallo, M; Maiello, MR; Morabito, A; Normanno, N; Perrone, F	1
Meldgaard, P; Nexo, E; Sorensen, BS; Tsai, J; Weber, B; Wei, W; Wu, L	1
Ge, N; Jiao, W; Qiu, T; Shen, Y; Tang, D; Wang, Y; Xuan, Y; Yan, G; Yao, R	1
Dickgreber, NJ; Hoffknecht, P; Maria Huber, R; Märten, A; Pelzer, T; Schütz, M; Serke, M; Stöhlmacher-Williams, J; Tufman, A; Wehler, T; Wiewrodt, R	1
Shawky, H; Tawfik, H	1
Abdulrahman, R; Ahn, C; Bunn, PA; Camidge, DR; Choy, H; Doebele, RC; Dowell, J; Gaspar, LE; Gerber, DE; Hughes, R; Iyengar, P; Kavanagh, BD; Smith, I; Timmerman, R; Wardak, Z	1
Arold, ST; Bartholomeusz, C; Blachno, KV; Boulbes, DR; Brady, SW; Chang, WC; Chauhan, GB; Deng, N; Esteva, FJ; Hsu, JM; Huang, TH; Hung, MC; Jin, Q; Ladbury, JE; Stone, S; Yu, D	1
Guo, S; Li, Z; Liu, Y; Ren, G; Ren, J; Song, G; Wang, Y; Zhang, L	1
He, X; Kong, Y; Li, W; Xiao, M; Zhang, H	1
Bregni, G; de Braud, F; Di Cosimo, S; Galli, G; Gevorgyan, A; Porcu, L; Serpico, D; Tessari, A; Torri, V	1
Becker, A; Heideman, DA; Kuiper, JL; Ronden, MI; Smit, EF; Thunnissen, E; van Hengel, P; Ylstra, B	1
Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Inoue, A; Isobe, H; Ito, K; Kinoshita, I; Kobayashi, K; Kurihara, M; Maemondo, M; Minato, K; Morita, S; Nishitsuji, M; Nukiwa, T; Oizumi, S; Sugawara, S; Yoshizawa, H	1
Bassermann, F; Becker, K; Eisenmenger, A; Haag, GM; Helbig, U; Karapanagiotou-Schenkel, I; Lordick, F; Lorenzen, S; Pohl, M; Riera Knorrenschild, J; Rüschoff, J; Schnoy, E; Stocker, G; Thuss-Patience, P; Weißinger, F	1
Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N	1
Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA	1
Bao, W; Cheng, SB; Chin, YE; Liu, N; Qiu, A; Shi, Y; Wang, L; Xiong, C; Xu, L; Yan, H; Yang, T; Zhuang, S	1
Hart, EM; Johnson, ML; Kris, MG; Patel, JD; Rademaker, AW; Riely, GJ; Weitner, BB; Yu, HA	1
Cai, JZ; Deng, H; He, WF; Li, QP; Liao, GY; Long, SQ; Pan, ZQ; Wu, WY; Xiao, SJ; Yang, XB; Zhou, YS	1
Dahlberg, SE; Jackman, DM; Jänne, PA; Johnson, BE; Lo, PC; Nishino, M; Oxnard, GR; Sequist, LV	1
Gemma, A; Hagiwara, K; Inoue, A; Isobe, H; Kobayashi, K; Maemondo, M; Miyauchi, E; Nukiwa, T; Oizumi, S; Saijo, Y; Sugawara, S; Yoshizawa, H	1
Bonetti, A; Giuliani, J; Martelli, S; Remo, A	1
Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II	1
Althouse, SK; Burns, M; Gubens, MA; Loehrer, PJ; Pedro-Salcedo, MS; Perkins, SM; Wakelee, HA	1
Butchbach, ME; Harris, AW	1
Miller, K; Morant, R; Stenzl, A; Wirth, M; Zuna, I	1
Agelaki, S; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kallergi, G; Kalykaki, A; Markomanolaki, H; Mavroudis, D; Papadaki, MA	1
Guckenberger, M	1
Fang, WF; Hong, SD; Huang, Y; Ma, YX; Sheng, J; Tian, Y; Xue, C; Yang, YP; Zhang, L; Zhao, YY	1
Appleton, CT; Beier, F; Mort, JS; Pest, MA; Pitelka, V; Usmani, SE	1
Ardizzoni, A; Chand, VK; Cobo, M; Felip, E; Gadgeel, SM; Georgoulias, V; Göker, E; Goss, GD; Guclu, SZ; Isla, D; Lee, KH; Li, W; Lu, S; Min, YJ; Morabito, A; Soria, JC; Syrigos, K; Wang, B	1
Ahn, MJ; Atagi, S; Jiang, H; Kim, SW; Lee, DH; Liu, Y; Lu, Y; Mok, TS; Nakagawa, K; Ponce, S; Shi, X; Soria, JC; Wang, J; Webster, A; Wu, YL; Yang, JC; Yang, JJ; Yoh, K; Zhou, JY	1
Chen, Q; Ding, L; Hong, X; Liang, Y; Quan, Q; Wu, H; Zhou, N	1
Aono, H; Azuma, K; Hosomi, Y; Kato, T; Komase, Y; Kunitoh, H; Morita, S; Nakahara, Y; Nishikawa, M; Oba, MS; Okamoto, H; Okuma, Y; Sato, A; Takeoka, H; Watanabe, K; Yamada, K	1
Anand, A; Carver, B; Heller, G; Larson, SM; Morris, MJ; Rathkopf, DE; Rosen, N; Scher, HI; Shaffer, DR; Slovin, SF	1
Anthoney, DA; Backen, AC; Beare, S; Bridgewater, JA; Corrie, P; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; Morris, K; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS	1
Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S	1
Casanova, C; Dazzi, C; Mazza, V; Verlicchi, A	1
Hwang, SG; Kim, EM; Park, JK; Um, HD	1
Cao, L; Guan, X; Shen, Y; Shi, Y; Sun, Z; Zhang, W	1
Aksu, S; Büyükaşık, Y; Eliaçık, E; Göker, H; Haznedaroğlu, İC; Işık, A; Özcebe, OI; Sayınalp, N; Üner, A	1
Aloj, L; Avallone, A; Bianco, F; Botti, G; Budillon, A; Caracò, C; Comella, P; Delrio, P; Granata, V; Iaffaioli, VR; Leone, A; Marone, P; Muto, P; Pecori, B; Petrillo, A; Romano, C; Romano, G; Tatangelo, F	1
Bueno, F; Cross, G; Lucas, S; Pitoia, F; Schmidt, A	1
Fu, F; Geng, J; Sun, D; Wang, H; Xie, X; Yu, G; Zhang, L	1
Beijnen, JH; Boss, DS; Grob, M; Huitema, AD; Keessen, M; Rehorst, H; Rosing, H; Schellens, JH; Smit, WM; Tibben, MM; van der Noll, R; Wymenga, AN	1
Bitterman, H; Feldhamer, I; Greenberg-Dotan, S; Hammerman, A; Yerushalmi, R	1
Ballantyne, CM; Barter, PJ; Borgman, M; Brewer, HB; Herrman, JP; Hu, B; Kastelein, JJ; Kataoka, Y; Merkely, B; Nicholls, SJ; Nissen, SE; Puri, R; Uno, K; Wolski, K	1
Gu, J; Hu, J; Mao, W; Sun, W; Sun, X; Wu, W; Xu, Y; Yu, X; Zhang, G; Zheng, Y	1
Abdel-Sattar, M; Sugay, A; Tien Ho, P; Ting, J; Wilson, L; Xiang, P	1
Fukusumi, M; Hamamoto, Y; Honma, C; Ibe, T; Kameyama, N; Kamimura, M; Mouri, A; Takeoka, S	1
Kim, H; Kim, HS; Kwon, JW; Shin, S; Sohn, HS	1
Bachelot, T; Barriere, J; Bono, P; Ciruelos, E; Cortés, J; Dieras, V; Espié, M; Hurvitz, S; Joensuu, H; Kellokumpu-Lehtinen, PL; Kim, SB; Le Rhun, E; Nabholtz, JM; Ould-Kaci, M; Piacentini, F; Ro, J; Roux, F; Schneeweiss, A; Sohn, JH; Taguchi, J	1
Goto, K; Matsumoto, S; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T	1
Hadoux, J; Pacini, F; Schlumberger, M; Tuttle, RM	1
Barrios, CH; Bines, J; Blajman, C; Capó, A; Fanelli, M; Fein, L; Gómez, HL; Ismael, G; Lerzo, G; Mano, M; Martínez-Mesa, J; Neciosup, S; Nerón, Y; Pinczowski, H; Sampaio, C; Santi, PX; Tosello, C; Varela, MS; Werutsky, G; Zarba, JJ	1
Chen, YW; Cheng, KH; Hsiao, PJ; Hung, WC; Kuo, KK; Su, HT; Weng, CC; Wu, DC	1
Bennouna, J; Chand, VK; Chen, YM; Chouaid, C; De Marinis, F; Feng, JF; Grossi, F; Kim, DW; Kim, JH; Liu, X; Lu, S; Park, K; Planchard, D; Schuler, M; Strausz, J; Vinnyk, Y; Wang, B; Wiewrodt, R; Yang, JC; Zhou, C	1
Liu, N; Mao, H; Qiu, A; Shi, Y; Wang, L; Xiong, C; Xu, L; Zang, X; Zhuang, S	1
Dahlberg, SE; Digumarthy, SR; Fulton, LE; Hatabu, H; Johnson, BE; Nishino, M; Sequist, LV	1
Beauchemin, C; Lachaine, J; Letarte, N; Mathurin, K; Yelle, L	1
Ahn, JS; Ahn, MJ; Lee, HY; Lee, JH; Lee, KS; Park, K; Sun, JM	1
An, C; Chu, H; Gu, C; Lu, R; Shi, H; Xiao, F; Yi, X; Zhang, H; Zhang, J; Zhu, F	1
Ikegami, D; Kuzumaki, N; Narita, M	1
Brown, N; Clifton-Hadley, L; Dungey, F; Hopkins, K; Jeffries, S; Khan, I; Krell, D; McBain, C; Mulholland, P; Nash, S; Phillips, M; Sanghera, P; Saran, F; Smith, P; Wanek, K	1
Chin, TM; Lee, JZ; Leow, YN; Lim, B; Lim, EH; Lim, EK; Lim, PX; Lim, WT; Lunny, DP; Malusay, SR; Nga, ME; Pang, YH; Shyh-Chang, N; Soo, RA; Sun, LL; Tai, BC; Tam, WL; Tan, BJ; Tan, DS; Tan, EH; Yang, H; Zhang, WC	1
Briner, C; Gladkov, O; Hsieh, RK; Kaneko, T; Koch, KM; LaBonte, MJ; Lee, WP; Lenz, HJ; Nagarwala, YM; Pishvaian, MJ; Rha, SY; Sakaeva, D; Urba, SG; Wilson, PM; Yang, D; Zhang, W	1
Ballard, P; Box, M; Cantarini, M; Cross, D; Grist, M; Hickey, M; Jänne, PA; Johnström, P; Jordan, A; Kim, DW; Malmquist, J; Pickup, K; Thress, KS; Varnäs, K; Yang, JC; Yang, Z; Yates, JW	1
Campo, M; Engelman, JA; Fidias, P; Gainor, JF; Gerber, D; Heist, RS; Muzikansky, A; Sequist, LV; Shaw, AT; Temel, JS	1
Bidoli, P; Buosi, R; Burgio, MA; Cappuzzo, F; Cerea, G; Chiari, R; Cortinovis, D; De Marinis, F; Del Conte, A; Ferrari, S; Finocchiaro, G; Foltran, L; Giannetta, L; Mazzoni, F; Migliorino, MR; Montanino, A; Morabito, A; Normanno, N; Tiseo, M	1
Guarino, M; Hanna, N; Jayaram, N; Masters, GA; Misleh, J; Patel, JD; Sanborn, RE; Stephens, A; Wu, J	1
Chang, TY; Chen, PS; Hsu, HP; Huang, MT; Kuo, KT; Lai, HH; Li, JN; Lyu, YJ; Su, CM; Su, JL	1
Demuth, C; Meldgaard, P; Sorensen, BS; Sorensen, SF; Weber, B	1
Antonelli, A; Baldini, E; Biricotti, M; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Ulisse, S	1
Aleksakhina, SN; Chubenko, VA; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Kozyreva, KS; Kramchaninov, MM; Mitiushkina, NV; Moiseyenko, FV; Moiseyenko, VM; Preobrazhenskaya, EV; Shelekhova, KV; Venina, AR; Volkov, NM; Zhuravlev, AS	1
Asmat, A; Kumarakulasinghe, NB; Loy, EY; Pang, B; Soo, RA; Soon, YY; Syn, N; Zheng, H	1
Bertolini, F; Bettelli, S; Longo, L; Manfredini, S; Mengoli, MC; Rossi, G	1
Li, P; Ma, Z; Wang, H; Yan, X; Zhang, G; Zhang, M	1
Pi, C; Xu, CR; Zhang, YC; Zhou, Q	1
Li, Y; Lu, H; Pan, J; Shi, Y; Xie, Z; Xu, Y; Zhang, M	1
Fraser, A	1
Heinemann, V; Stemmler, HJ	1
Chen, Z'; Khuri, FR; Lee, JE; Shin, DM; Shin, HJ; Tighiouart, M; Yang, CS; Zhang, H; Zhang, X	1
Ahn, JS; Ahn, MJ; Cho, JY; Choi, JH; Holmes, AJ; Jänne, PA; Kang, JH; Ki, CS; Kim, HT; Kim, SW; Lee, JS; Park, BB; Park, CK; Park, K; Park, SH; Shin, SW; Sohn, CH; Song, HS	1
Baselga, J; Cedres, S; Felip, E; Foernzler, D; Gatzemeier, U; Heller, A; Klughammer, B; Maacke, H; Möcks, J; Parera, M; Peralta, S; Reck, M; Rojo, F; Sala, G; Saura, C	1
Becker, M; Börgermann, C; Rose, A; Rübben, H; Vom Dorp, F	1
Cameron, DA; Stein, S	1
Bernhard, JC; Ferrière, JM; Ravaud, A; Robert, G; Wallerand, H	1
Ishikawa, H; Kikuchi, N; Ohara, G; Satoh, H; Sekizawa, K	1
Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M	1
Spector, N	1
Armour, AA; Cappuzzo, F; Crinò, L; Cullen, M; Duffield, EL; Ford, HE; Ghiorghiu, S; Hirsch, FR; Pesek, M; Reck, M; Speake, G; Thompson, JC; Varella-Garcia, M; Zatloukal, P	1
Alloisio, M; Cappuzzo, F; Destro, A; Finocchiaro, G; Incarbone, M; Jänne, PA; Ligorio, C; Roncalli, M; Rossi, E; Santoro, A; Skokan, M; Terracciano, L; Toschi, L; Varella-Garcia, M; Zucali, PA	1
Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R	1
Bonomi, PD; Cohen, G; De Braud, F; Eberhardt, WE; Herbst, RS; Heymach, JV; Johnson, BE; Krebs, AD; Paz-Ares, L; Ranade, AA; Sandler, AB; Sebastian, M; Stewart, DJ; Trigo, JM; Vasselli, J	1
Camara, O; Egbe, A; Hammer, U; Hoeffken, K; Jörke, C; Pachmann, K; Rabenstein, C; Runnebaum, IB	1
Aglietta, M; Botti, G; Bottini, A; Clavarezza, M; Danese, S; dei Tos, AP; del Curto, B; Di Bonito, M; Di Palma, S; Donadio, M; Durando, A; Jacomuzzi, ME; Kulka, J; Montemurro, F; Redana, S; Sanna, G; Sapino, A; Valabrega, G; Viale, G	1
Arusell, R; Brown, PD; Buckner, JC; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Jenkins, RB; Kitange, G; Krishnan, S; Kugler, JW; Mischel, P; Morton, RF; Rowland, KM; Sarkaria, JN; Scheithauer, BW; Schiff, D; Uhm, JH; Wu, W; Yong, WH	1
Donovan, JC; Ghazarian, DM; Shaw, JC	1
Dobrova, NV; Lichinitser, MR; Semenov, NN; Vakhabova, JV	1
Ren, SX; Yan, LH; Zhang, L; Zhou, CC; Zhou, SW	1
Babayan, RK; Wiygul, J	1
Choi, Y; Kim, JE; Kim, SW; Lee, DH; Lee, JS; Suh, C; Yoon, DH	1
Arbushites, MC; Blackwell, KL; Burstein, HJ; Forster, JK; Maltzman, JD; Pegram, MD; Rubin, SD; Schwartzberg, LS; Stein, SH; Tan-Chiu, E	1
Davidson, CR; Hardie, WD; Ikegami, M; Korfhagen, TR; Le Cras, TD; Schmidt, SM; Whitsett, JA	1
Lin, CC; Yang, CH	1
Kunitoh, H; Saijo, N; Takeuchi, M	1
Beuzeboc, P; De Groot, MR; El-Hariry, IA; Grimm, MO; Machiels, JP; Parikh, R; Pétavy, F; Richel, DJ; Treiber, U; Wülfing, C	1
Manegold, C	1
Bartha, E; Halmosi, R; Hideg, K; Kálai, T; Kereskai, L; Lantos, J; Magyar, K; Plozer, E; Solti, I; Sumegi, B; Szabados, E; Toth, K	1
Dhruva, N; Socinski, MA	1
Han, JY; Kang, KW; Kim, HT; Kim, HY; Kim, SK; Lee, DH; Lee, HY; Lee, JS; Lee, SY; Park, SH	1
Ayabe, E; Endo, M; Igawa, S; Kaira, K; Kaira, R; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shimoyama, R; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N	1
Antoine, M; Baudrin, L; Cadranel, J; Isaac-Sibille, S; Lebitasy, MP; Longchampt, E; Neuville, A; Poulot, V; Pradere, M; Wislez, M	1
Hanagiri, T; Nose, N; Onitsuka, T; Sugio, K; Takenoyama, M; Uramoto, H; Yasumoto, K	1
Jiang, W; Wu, JX; Xue, C; Zhang, L; Zhang, Y; Zhao, HY; Zhao, YY	1
Ren, S; Tang, L; Yan, L; Zhang, J; Zhang, L; Zhou, C; Zhou, S	1
Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM	1
Balint, C; Bekaii-Saab, T; Campbell, A; Chen, H; Culler, K; Dai, Z; Dancey, J; Eng, C; Grever, M; Heerema, N; Lee, RM; Markowitz, J; O'Neil, B; Papp, A; Prescott, N; Sadee, W; Villalona-Calero, M; Wei, L; Zalupski, M	1
Allen, KE; Aogi, K; Arai, T; Ellis, CE; Fujiwara, Y; Gagnon, RC; Ito, Y; Iwata, H; Katsura, K; Nakamura, S; Rai, Y; Sasaki, Y; Taguchi, T; Takashima, S; Toi, M; Tokuda, Y; Wakamatsu, T; Watanabe, J	1
Bonnichon, A; Le Floch, H; Mairovitz, A; Margery, J; Rivière, F; Staub, E; Vaylet, F	1
Afifi, Y; Benomar, S; Bouhllab, J; Boutayeb, S; Errihanni, H; Hamada, S; Hassam, B	1
Beer, PA; Green, AR	1
Amann, JM; Brahmer, J; Carbone, DP; Gonzalez, A; Lee, JW; Roder, H; Schiller, JH	1
Billheimer, D; Carbone, DP; Chen, H; Dang, TP; Herbst, RS; Roder, H; Roder, J; Salmon, JS; Sandler, A; Tran, HT; Tsao, AS; Tsypin, M	1
Ardavanis, A; Doufexis, D; Karagiannis, A; Kountourakis, P; Rigatos, G; Tzovaras, AA	1
Chang, J; Cho, BC; Choi, HJ; Kim, JH; Kim, SK; Lee, YJ; Moon, JW; Park, IK	1
Ardinghi, C; Bani, MR; Bernasconi, S; Carraro, F; Ghilardi, C; Giavazzi, R; Naldini, A; Oliva, P; Silini, A	1
Bergsland, EK; Dito, E; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Schillinger, B; Scott, J; Tempero, MA; Venook, AP	1
Brandes, AA; Degli Esposti, R; Franceschi, E; Tosoni, A	1
Caicun, Z; Jian, G; Jie, Z; Liang, T; Ling, Z; Qinfang, D; Songwen, Z	1
Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S	1
Butler, JS; Donahue, BR; Huang, Y; Olmez, I; Rubin, P; Xu, Y	1
Belani, CP; Owonikoko, TK; Ramalingam, SS	1
Liao, ML; Qin, SK; Sun, Y; Wu, YL; Zhou, CC	1
Hotta, K; Inoue, K; Kishino, D; Kiura, K; Okada, T; Suzuki, E; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H	1
Anthoney, A; Blatter, J; Dean, E; Hanauske, AR; Kletzl, H; Klingelschmitt, G; Melezinek, I; Ranson, M; Reck, M; Twelves, C	1
Guo, P; Kris, MG; Ladanyi, M; Moskowitz, CS; Oxnard, GR; Pao, W; Rizvi, NA; Rusch, VM; Schwartz, LH; Zhao, B	1
Abrahámová, J; Bacanu, F; Brincat, S; Brize, A; Cesas, A; Cufer, T; Dank, M; Duchnowska, R; Eniu, A; Jassem, J; Kahán, Z; Matos, E; Padrik, P; Plāte, S; Pokker, H; Purkalne, G; Steger, GG; Timcheva, C; Tzekova, V; Vyzula, R; Zielinski, CC	1
Dunn, EF; Harari, PM; Wheeler, DL	1
Brückl, WM; Ficker, JH; Wiest, GH	1
English, JF; Erridge, SC; Ironside, JA; Kerr, GR; Little, FA; Mackean, MJ; Price, A	1
Chang, HC; Connolly, K; DiGiovanni, J; Kiguchi, K; Kitamura, T; Moore, T; Ruffino, L; Rumi, M; Treece, D	1
Cioffredi, LA; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Van den Abbeele, AD; Yap, JT; Yeap, BY	1
Barker, FG; Batchelor, TT; Halpin, C; Loeffler, JS; McKenna, MJ; Plotkin, SR	1
Baselga, J; Casado, E; Cervantes, A; Chirivella, I; Elvin, P; Hamberg, P; Hoekman, K; Hurwitz, HI; Iacona, R; Jodrell, DI; Martinelli, E; Swaisland, A; Tabernero, J	1
Cho, EK; Hong, J; Jung, SH; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ	1
Andreasson, I; Boér, K; Láng, I; Llombart-Cussac, A; Murray, E; Pover, GM; Sanders, N; Vivanco, GL	1
Andreuccetti, M; Borghi, F; Caparello, C; Caponi, S; D'Incecco, A; Falcone, A; Ginocchi, L; Lucchesi, M; Tibaldi, C; Vasile, E	1
Fujiwara, K; Kudo, K; Matsuo, K; Mizuta, M; Sato, T; Tsushima, M; Yonei, T	1
Fusi, A; Keilholz, U; Liu, Z; Schmittel, A; Schneider, A; Tinhofer, I	1
Egerton, N	1
Barriuso, J; Belda-Iniesta, C; Borrega, P; Castro, J; Feliu, J; González-Barón, M; León, A; López, M; López-Gómez, L; Martínez, V	1
Saijo, N	1
Dempke, W; Zippel, R	1
Britt, GJ; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Rabin, MS; Yeap, BY	1
Alberts, DS; Baker, AF; Brewer, MA; Chambers, SK; Clouser, MC; Cohen, JL; Cui, H; Gordon, AN; Gordon, MS; Hatch, KD; Isaacs, JD; Janicek, MF; Nagle, RB; Roe, DJ; Wright, HM	1
Crawford, H; Ely, M; Janakiram, NB; Li, Q; Lightfoot, S; Madka, V; Mohammed, A; Rao, CV; Steele, VE	1
Colucci, G; Galetta, D; Millaku, A; Pisconti, S; Rossi, A	1
Chen, E; Gauthier, I; Gill, S; Goel, R; Hedley, D; Jonker, D; McIntosh, L; Moore, MJ; Renouf, DJ; Seymour, L; Southwood, B; Walde, D; Walsh, W	1
Bekele, BN; Guo, CC; Marcott, V; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM; Wen, S	1
Durbin, JE; Koromilas, AE; Muller, WJ; Raven, JF; Tremblay, ML; Wang, S; Williams, V	1
Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yatabe, Y; Yokota, T	1
Brachtel, E; Chiba, N; Edelman, EJ; Hayashida, T; Maheswaran, S; Moriyama, H; Ramaswamy, S; Shimada, T; Tajima, K; Takahashi, F; Takahashi, M	1
Chang, DS; Di, YP; Li, HQ; Li, P; Liu, LY; Wang, J; Wang, JD; Wang, X; Wang, YJ; Wu, WZ; Xia, TY	1
Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B	1
Amler, LC; Charu, V; Fine, BM; Gitlitz, BJ; Hicks, RJ; Hughes, BG; Macfarlane, D; Mileshkin, L; Mitchell, PL; Pirzkall, A; Solomon, B; Yu, W	1
Chen, X; Guo, R; Shu, Y; Sun, J; Wang, T; Zhang, Z	1
Takami, HE	1
Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Wislez, M	1
Heigener, DF; Horwood, K; Mali, P; Reck, M; van Zandwijk, N; Wu, YL	1
Chi, HD; Chua, D; Jiang, ZF; Liu, DG; Luo, RC; Martin, AM; Newstat, B; Preston, A; Shao, ZM; Wang, L; Wang, XJ; Xu, BH; Yeo, W; Yu, SY	1
Abbate, I; Bongarzone, I; Cremona, M; De Bortoli, M; Galetta, D; Garrisi, VM; Mangia, A; Paradiso, A; Pastorino, U; Quaranta, M; Vaghi, E	1
Kern, I; Kovac, V; Rajer, M; Smrdel, U; Vrankar, M; Zwitter, M	1
Abdiche, S; Bonnabau, H; Chouaïd, C; Cumin, I; Decroisette, Ch; Ejnaini, CN; Hureaux, J; Lombard, JN; Mazières, J; Monnet, I; Quéré, G; Vergnenègre, A	1
Alberti, D; Bowen, CJ; Dar, MM; Dennie, TW; Fleming, RA; Holen, KD; Loconte, N; Mulkerin, D; Oliver, K	1
Ma, S; Xu, Y; Zhang, Y	1
Alvarez, RH; Cristofanilli, M; De Giorgi, U; De Laurentiis, M; De Placido, S; Giordano, A; Giuliano, M; Handy, BC; Hess, KR; Hortobagyi, GN; Jackson, S; Mego, M; Reuben, JM; Ueno, NT; Valero, V	1
Ameshima, S; Asami, K; Atagi, S; Hirai, K; Kawahara, M; Koizumi, T; Morikawa, A; Morozumi, N; Tsukadaira, A	1
Barlesi, F	1
Houwing, RH; Koster, ME; Lips, IM; Vonk, EJ	1
Blanchet, B; Goldwasser, F; Mir, O	1
Biswas-Baldwin, N; Bourhis, J; Carracedo, C; Compton, N; Cupissol, D; De Raucourt, D; Del Campo, JM; Downie, L; El-Hariry, I; Harrington, KJ; Hitt, R; Lokanatha, D; Maroudias, N; Midwinter, D; Nutting, CM; Sebastian, P; Temam, S	1
Chaft, JE; Kris, MG; Miller, VA; Oxnard, GR; Riely, GJ; Sima, CS	1
Chua, KT; Lai, NL; Lee, CH; Liam, CK; Lim, BK; Pang, YK	1
Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A	1
Bachi, A; Bergamaschi, L; Bulotta, A; Cattaneo, A; Floriani, I; Garavaglia, D; Ghio, D; Gregorc, V; Grigorieva, J; Lazzari, C; Roder, H; Sorlini, C; Spreafico, A; Tsypin, M; Viganò, MG	1
Guo, J; Liu, Y; Wang, Y; Wang, Z; Yang, J	1
Cho, J; Chowhan, NM; Funke, R; Gadgeel, SM; Lara, PN; Lynch, TJ; Miller, VA; Mitchell, B; Pennell, NA; Pietanza, MC; Vrindavanam, N; Wakelee, HA; Yanagihara, RH	1
Eguchi, S; Fujigaki, Y; Hishida, A; Suzuki, H; Yamamoto, T	1
Baudin, E; Dralle, H; Elisei, R; Fagin, JA; Gagel, RF; Jarzab, B; Langmuir, P; Read, J; Robinson, BG; Ryan, AJ; Santoro, M; Schlumberger, MJ; Vasselli, JR; Wells, SA	1
Bisagni, G; Clavarezza, M; Cognetti, F; Crivellari, D; Fabi, A; Ferzi, A; Foglietta, J; Gamucci, T; Gori, S; Metro, G; Montemurro, F; Silva, RR; Spazzapan, S; Stocchi, L; Torrisi, E	1
Allen-Auerbach, MS; Benz, MR; Czernin, J; Figlin, R; Garon, EB; Herrmann, K; Phelps, ME; Reckamp, KL; Walter, F; Weber, WA	1
Arteaga, CL; Gianni, L; Osborne, CK; Perez, EA; Puglisi, F; Sliwkowski, MX	1
Ancukiewicz, M; Batchelor, TT; Emblem, KE; Ivy, P; Jain, RK; Jennings, D; Kim, H; Polaskova, P; Sorensen, AG; Wang, M; Wen, PY	1
Appleyard, CB; Coppola, D; Cruz, ML; Isidro, AA; Pagán, B; Ren, Y; Wu, J	1
Bubley, GJ; Buckle, GC; Choueiri, TK; Eisenberger, MA; Hahn, NM; Hutson, TE; Jacobus, S; Kantoff, PW; Kim, WY; Morrissey, SC; Mortazavi, A; Petrylak, DP; Quinn, DI; Rosenberg, JE; Ross, RW; Ryan, CW; Sonpavde, G; Taplin, ME; Vaishampayan, U; Yu, EY	1
Chang, HM; Chang, JS; Choi, HJ; Jang, JS; Jeung, HC; Kang, HJ; Kang, JH; Kang, WK; Kim, JS; Lee, HW; Lee, J; Lee, MA; Lim, HY; Park, JO; Park, SH; Park, YS; Shin, DB; Sun, JM	1
Endo, M; Harada, H; Inomata, M; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N	1
Bekele, BN; Biernacka, A; Erez, B; Herbst, RS; Hosho, K; Jacoby, JJ; Jürgensmeier, JM; Komaki, R; Korshunova, MV; O'Reilly, MS; Ryan, A; Smith, PD; Takahashi, O; Wistuba, II	1
Barletta, G; Boldrini, L; Brianti, A; Cosso, M; Dal Bello, MG; Defferrari, C; Fontanini, G; Genova, C; Grossi, F; Murolo, C; Pronzato, P; Rijavec, E; Truini, M	1
Fan, Q; Li, P; Ma, Z; Qi, G; Wang, H; Wang, Q; Yan, X; Zhang, G; Zhu, H	1
Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Greillier, L; Jullian, H; LeCaer, H; Vergnenegre, A	1
Carey, LA; Cleator, S; Frakes, L; Garcia, AA; Hickish, T; Houston, S; Jones, H; Kelly, S; Lin, NU; Mendelson, D; Munster, P; Uttenreuther-Fischer, M; Vinisko, R; Wheatley, D; Wind, S; Winer, EP	1
Kawada, A; Nakagawa, K; Oiso, N; Okamoto, I; Takeda, M; Tsurutani, J	1
Chen, LK; Dinglin, XX; Liang, Y; Liao, H; Liu, JL; Xu, F; Zeng, YD; Zhang, L	1
Harada, H; Mitsuya, K; Mizokami, Y; Nakamura, Y; Nakasu, Y; Nishimura, T; Ono, A; Takahashi, T; Toda, Y; Yamamoto, N	1
Ahn, JS; Ahn, MJ; Hwang, IG; Jo, SJ; Kim, BS; Kim, HK; Kim, SW; Kim, YH; Lee, DH; Lee, JW; Lee, K; Lee, KH; Min, YJ; Park, K; Song, HS; Sun, JM; Yun, HJ	1
Arbushites, MC; Bernini, P; Bertini, I; Biganzoli, L; Cappadona, S; Claudino, WM; Di Leo, A; Luchinat, C; Nepi, S; Oakman, C; Tenori, L	1
Britt, GJ; Butaney, M; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Joshi, VA; Lindeman, NI; Rabin, MS; Yeap, BY	1
Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R	1
Ahn, JS; Ahn, MJ; Cho, SH; Choi, YL; Han, JH; Hwang, DW; Ji, JH; Lee, JY; Park, K; Park, LC; Park, S; Sun, JM	1
Jelsing, J; Klein, T; Mark, M; van Witteloostuijn, SB; Vrang, N	1
Alam, Y; Butts, C; Cantile, F; Ciardiello, F; Cinieri, S; da Cunha Santos, G; Di Maio, M; Favaretto, A; Feld, R; Felletti, R; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, N; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, A; Saieg, M; Siena, S; Tortora, G; Tsao, MS; Wierzbicki, R	1
Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A	1
Abdul Razak, M; Chan, LC; Ong, CK; Tan, WC	1
Al-Shahrour, F; Alexander, D; Baran, M; Carretero, J; Difilippantonio, S; El Meskini, R; Guerin, T; Gumprecht, M; Iacovelli, AJ; Kozlov, S; Kulaga, A; Martin, PL; McCann, T; Mena, S; Schlomer, J; Van Dyke, T; Weaver, Z; Wong, KK	1
Benjamin, L; Buthion, V; Farah, B; Iskedjian, M; Rioufol, C; Vidal-Trécan, G	1
Betticher, D; Brauchli, P; Bubendorf, L; Crowe, S; Droege, C; Froesch, P; Gautschi, O; Hess, T; Mayer, M; Ochsenbein, A; Oppliger Leibundgut, E; Pless, M; Rauch, D; Ribi, K; Schmid, P; Stahel, R; von Moos, R; Zappa, F	1
Brenker, K; Choi, K; Durand, CA; Gold, MR; Graves, M; Horwitz, MS; Puri, KD; Richer, MJ; Shanina, I	1
Edelman, MJ; Mok, T; O'Byrne, K; Paz-Ares, L; Rittweger, K; Spigel, DR; Thurm, H; Yu, W	1
Somogyi, A	1
Bertossi, M; De Sanctis, R; De Vincenzo, F; Di Tommaso, L; Fattuzzo, G; Giordano, L; Lorenzi, E; Mancini, L; Masci, G; Perrino, M; Rimassa, L; Roncalli, MG; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA; Zuradelli, M	1
Aisner, DL; Bunn, PA; Burke, JM; Camidge, DR; Doebele, RC; Gan, G; Gaspar, LE; Kavanagh, BD; Lu, X; Scheier, B; Weickhardt, AJ	1
Li, X; Lü, JL; Qin, N; Sun, YF; Wu, YH; Yang, XJ; Zhang, H; Zhang, Q; Zhang, SC	1
Gridelli, C; Maione, P; Rossi, A	1
Asami, K; Atagi, S; Hirashima, T; Kawaguchi, T; Kawahara, M; Okishio, K; Okuma, T; Omachi, N; Takeuchi, N	1
Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X	1
Chen, EX; Haider, MA; Halford, R; Hotte, SJ; Ivy, SP; Kollmannsberger, C; Mackenzie, MJ; Moore, MJ; Mukherjee, SD; Murray, N; Sridhar, SS; Tannock, IF; Wang, L	1
Bakris, GL; Flynn, C	1
Selam, M	1
Depisch, D; Fiebiger, W; Kornek, GV; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H	1
Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H	1
Barthélemy, P; Daniel, C; Doubre, H; Fandi, A; Fizazi, K; Le Chevalier, T; Riviere, A; Robert, L; Ruffié, P; Viala, J	1
Cain, D; James, RD; Kerr, DJ; Ledermann, JA; Maughan, TS; McArdle, C; Seymour, MT; Stephens, RJ; Topham, C	1
Aebi, S; Borner, MM; Büchler, MW; Friess, H; Kralidis, E	1
Glimelius, B	1
Boige, V; Ducreux, M	1
Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, KE; Schüll, B	1
Aparicio, J; Bosch, C; Busquier, I; Díaz, R; Fernández-Martos, C; Galán, A; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM	1
Bartolini, S; Calandri, C; Cancellieri, A; Cappuzzo, F; Ceresoli, G; Crino, L; de Rosa, M; Gregorc, V; Lombardo, L; Magrini, E; Paties, CT; Rossi, E; Villa, E	1
O'Leary, MP	1
Dafni, H; Gross, DJ; Nagler, A; Neeman, M; Pines, M; Reibstein, I; Slavin, S; Weiss, L	1
Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L	1
Natale, RB	1
Khuri, FR	1
Alloisio, M; Campagnoli, E; Cavina, R; Ferrari, B; Ginanni, V; Latteri, F; Morenghi, E; Pedicini, V; Ravasi, G; Roncalli, M; Santoro, A; Soto Parra, HJ; Zucali, PA	1
Asai Go, Go; Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Tamura, K; Uejima, H	1
Agarwala, SS; Hidalgo, M; Senzer, NN; Siu, LL; Soulieres, D; Vokes, EE	1
Adam, L; Bagheri-Yarmand, R; Barnes, CJ; Clayman, GL; El-Naggar, A; Hong, WK; Kumar, R; Lotan, R; Papadimitrakopoulou, VV; Wang, RA; Yang, Z	1
Kim, R; Toge, T	1
Barón, MG; Castañón, C; de Tejada, MR; Escudero, P; Feliu, J; López-Gómez, L; Martín, MS; Martínez, MP; Pericay, C; Rodríguez-García, JM; Salud, A; Sánchez, JJ	1
Fidias, P; Gurubhagavatula, S; Jänne, PA; Johnson, BE; Lucca, J; Lynch, TJ; Ostler, P; Skarin, AT; Yeap, BY	1
Baas, P; Haringhuizen, A; Vaessen, HF; van Tinteren, H; van Zandwijk, N	1
Alfonso, R; Averbuch, S; Fandi, A; Giaccone, G; González-Larriba, JL; Martens, M; Peters, GJ; Smit, EF; Smith, R; van der Vijgh, WJ; van Oosterom, AT	1
Argiris, A; Mittal, N	1
Barbui, T	1
Perez-Soler, R	1
Giaccone, G	1
Im, YH; Jung, CW; Kang, WK; Kim, HY; Kim, JH; Kim, JY; Kim, K; Lee, KE; Lee, MH; Lee, SH; Lee, SI; Park, BB; Park, J; Park, JO; Park, K; Park, SH; Park, YS	1
Bartolini, S; Bellezza, G; Calandri, C; Cancellieri, A; Cappuzzo, F; Ceresoli, GL; Crinò, L; Damiani, S; Gregorc, V; Ligorio, C; Lombardo, L; Ludovini, V; Magrini, E; Paties, CT; Rossi, E; Spreafico, A; Tonato, M	1
Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, NK; Kim, TY; Kim, YT	1
Bencardino, KB; Cappuzzo, F; Ceresoli, GL; Crinò, L; Ferraldeschi, M; Floriani, I; Gregorc, V; Ludovini, V; Mihaylova, Z; Pistola, L; Spreafico, A; Tofanetti, FR; Tonato, M; Torri, V; Villa, E	1
de Waal, R; Heerschap, A; Küsters, B; Leenders, WP; Maass, C; Ruiter, D; Ryan, A; Verrijp, K; Wesseling, P	1
del Giglio, A; Ito, C	1
Baetz, T; Berry, S; Brundage, M; Canil, CM; Chi, KN; Douglas, L; Ernst, DS; Fisher, B; McKenna, A; Moore, MJ; Pollak, M; Seymour, L; Winquist, E	1
du Bois, A; Eiermann, W; Fasching, P; Hilfrich, J; Jonat, W; Kettner, E; Kleeberg, U; Lück, HJ; Schneeweiss, A; Torode, J; von Minckwitz, G	1
Berlin, JD; Lockhart, AC; Lockhart, C	1
Kris, MG; Miller, VA; Pao, W; Politi, KA; Riely, GJ; Somwar, R; Varmus, H; Zakowski, MF	1
Ahn, SJ; Baek, SM; Jeong, JY; Kim, KS; Kim, YC; Kim, YH; Kim, YI; Lim, SC; Na, KJ; Park, CM; Park, CS; Park, KO	1
Govindan, R; Green, MR; Herndon, JE; Kindler, HL; Kratzke, RA; Niehans, GA; Vollmer, R; Watson, D	1
Han, JY; Hong, EK; Kim, HK; Kim, HY; Lee, DH; Lee, EK; Lee, HG; Lee, JJ; Lee, JS	1
Gatzemeier, U; Reck, M	1
Fehrenbacher, L; Herbst, RS; Hermann, R; Johnson, BE; Johnson, DH; Klein, P; Kris, MG; Li, X; Miller, VA; Prager, D; Ramies, D; Sandler, A; Tran, HT	1
Bearz, A; Berretta, M; Spazzapan, S; Tirelli, U; Vaccher, E	1
Altundag, K; Altundag, O; Boruban, C; Silay, YS	1
Edakuni, N; Inayama, M; Kakiuchi, S; Muguruma, H; Nakataki, E; Nishikubo, N; Ohtsuka, S; Sone, S; Tomimoto, H; Yano, S	1
Chen, A; Chen, ZG; Choe, MS; Khuri, FR; Lin, Y; Shin, DM; Shin, HJ; Sun, SY; Wieand, HS; Zhang, X	1
Fridman, E; Genina, O; Mor, Y; Nagler, A; Pines, M; Pinthus, JH; Sheffer, Y	1
Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T	1
Edelman, MJ	1
Ceribelli, A; Cognetti, F; Gelibter, A; Milella, M; Moscetti, L; Pollera, CF; Sperduti, I	1
Abrey, LE; Chang, S; Cowell, JK; DeAngelis, LM; Gilbert, MR; Grefe, CN; Holland, EC; Kuhn, JG; Lamborn, K; Lassman, AB; Lieberman, FS; Nowak, NJ; Pao, W; Prados, M; Raizer, JJ; Razier, JR; Rossi, MR; Shih, AH; Wen, P; Wilson, R; Yung, WA	1
Bartolini, S; Bemis, L; Bunn, PA; Cancellieri, A; Cappuzzo, F; Ceresoli, GL; Crino, L; Domenichini, I; Franklin, WA; Hirsch, FR; Ludovini, V; Magrini, E; Rossi, E; Toschi, L; Varella-Garcia, M	1
Dudek, AZ; Keshtgarpour, M; Kmak, KL; Koopmeiners, J	1
Ali, N; Fujita, Y; Ishizawa, K; Izawa, Y; Kanematsu, Y; Ohnishi, H; Tamaki, T; Tsuchiya, K; Yoshizumi, M	1
Benson, AB; Berlin, JD; Coffey, RJ; LaFleur, B; Levy, DE; Morgan-Meadows, SL; Ramanathan, RK; Rothenberg, ML; Washington, MK	1
Baron, A; Bunn, PA; Chan, DC; Chan, Z; Coldren, CD; Drabkin, HA; Dziadziuszko, R; Franklin, W; Gazdar, AF; Gemmill, RM; Girard, L; Hedman, K; Helfrich, B; Hirsch, FR; Minna, JD; Ravdel, L; Sugita, M; Witta, SE	1
Armitage, JN; Emberton, M	1
A'Hern, RP; Box, C; D'Ambrosio, C; Eccles, SA; Harrington, KJ; Kirby, AM; Nutting, CM; Rogers, SJ; Syrigos, KN; Tanay, M	1
Fitzpatrick, JM	1
Emberton, M	1
Aprile, G; Balzano, G; Bonetto, E; Brandes, AA; Cordio, S; Dell'Oro, S; Di Carlo, V; Fugazza, C; Luppi, G; Milandri, C; Nicoletti, R; Pasetto, L; Passoni, P; Piemonti, L; Reni, M; Zerbi, A	1
Roehrborn, CG	1
Hennemann, B	1
Reck, M	1
Chen, E; Dancey, J; Hedley, D; Ho, J; Major, P; Moore, MJ; Nicklee, T; Oza, AM; Pond, GR; Siu, LL; Townsley, CA; Tsao, M	1
Goto, K; Park, K	1
Leow, CH; Liam, CK; Pang, YK	1
Bianco, AR; Caputo, F; Catalano, G; Ciardiello, F; Colantuoni, G; De Laurentiis, M; De Placido, S; De Vita, F; Diadema, MR; Gridelli, C; Orditura, M; Palmieri, G; Tortora, G; Troiani, T	1
Pérol, M	1
Costa, DB; Schumer, ST	1
Dubinett, SM; Elashoff, RM; Figlin, RA; Krysan, K; Milne, GL; Morrow, JD; Newman, RA; Reckamp, KL; Tucker, C	1
Allmer, C; Donehower, RC; Erlichman, C; Fitch, T; Kim, G; Mahoney, MR; Philip, PA; Picus, J; Pitot, HC; Thomas, J	1
Bell, DW; Haber, DA; Halmos, B; Holmes, AJ; Huberman, MS; Jackman, DM; Jänne, PA; Johnson, BE; Joshi, VA; Lindeman, N; Lynch, TJ; Meyerson, M; Rabin, MS; Sequist, LV; Yeap, BY	1
Holloway, B; Kasahara, K; Kawaishi, M; Kimura, H; Kunitoh, H; Nishio, K; Tamura, T	1
Charoentum, C	1
Azzoli, CG; Dunne, M; Gomez, JE; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Milton, DT; Pao, W; Rizvi, NA; Venkatraman, E	1
Craddock, L; Darby, A; Geldart, T; Iveson, A; Iveson, T; Michels, J; Richardson, L	1
Fujiwara, Y; Hotta, K; Kiura, K; Segawa, Y; Shinkai, T; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S	1
Endoh, H; Hida, T; Kosaka, T; Kuwano, H; Mitsudomi, T; Tada, H; Tsuboi, M; Yatabe, Y; Yoshida, K	1
Asahina, H; Dosaka-Akita, H; Fujita, Y; Harada, M; Ishida, T; Isobe, H; Kinoshita, I; Kojima, T; Nishimura, M; Ogura, S; Okamoto, Y; Sukoh, N; Yamazaki, K; Yokouchi, H	1
Heelan, RT; Kris, MG; Miller, VA; Milton, DT; Pao, W; Riely, GJ	1
Giaccone, G; Hoekman, K; Kater, M; Manoliu, RA; Meijerink, MR; van Cruijsen, H; van Schaik, C; van Waesberghe, JH	1
An, TT; Fang, J; Liu, XY; Wu, MN; Yang, L	1
Hughes, S; Meehan, L; Moore, S; Norton, A; O'Brien, M; Papadopoulos, P; Popat, S; Priest, K; Wilkins, A	1
Han, Y; Li, YM; Paradiso, A; Wang, Y; Xu, JM; Zhao, CH	1
Berger, M; Cameron, D; Campone, M; Chan, A; Chan, S; Crown, J; Davidson, N; Forster, J; Geyer, CE; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Oliva, C; Pienkowski, T; Romieu, CG; Rubin, SD; Skarlos, D; Stein, S	1
Muss, HB	1
García-Foncillas, J; Gil, C; Monreal, I; Rodríguez, J; Salgado, J; Zabalegui, N	1
Abe, T; Haraguchi, M; Hayashi, M; Ito, K; Tsutsui, N	1
Dobashi, K; Hisada, T; Iijima, H; Ishizuka, T; Kaira, K; Mori, M; Saito, R; Shimizu, K; Suga, T; Sunaga, N; Tanaka, S; Tomizawa, Y; Yanagitani, N	1
Argiris, A; Gooding, W; Hensing, T; Kolesar, J; Masters, G; Patel, S; Pins, M; Raji, A; Sturgis, C; Yeldandi, A	1
Bunn, PA; Dziadziuszko, R; Hirsch, FR; Jassem, J; Limon, J; Rzyman, W; Siemiatkowska, A; Varella-Garcia, M	1
Basu, S; Bonomi, P; Buckingham, LE; Coon, JS; Gale, M; Jacobson, KK; Jewell, SS; Kaiser, KA; Mauer, AM; Morrison, LE; Muzzafar, T; Polowy, C; Villaflor, VM	1
Bekele, BN; Herbst, RS; Liu, DD; Massarelli, E; Ozburn, NC; Tang, X; Varella-Garcia, M; Wistuba, II; Xavier, AC	1
Cescon, TP; Dennison, SK; Geyer, CE; Jacobs, SA; Raymond, JM; Seeger, J; Swain, SM; Wilson, JW; Wolmark, N	1
Costa, DB	1
Han, Y; Li, YM; Liu, XQ; Song, ST; Xu, JM; Yang, WW; Zhang, Y	1
Chang, J; Cho, BC; Choi, HJ; Im, CK; Kim, H; Kim, JH; Kim, SK; Kim, YJ; Park, JP; Park, MS; Shin, SJ; Sohn, JH	1
Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L	1
Borner, M; Knuth, A; Morant, R; Pedrazzini, A; Rochlitz, C; Roggero, E; Salzberg, M; Schönenberger, A; Thalmann, G	1
Botwood, N; Carbone, D; Danson, S; Dunlop, D; O'Byrne, KJ; Ranson, M; Taguchi, F	1
Curigliano, G; De Braud, F; De Cobelli, O; De Pas, T; Matei, V; Noberasco, C; Nolè, F; Renne, G; Rocco, B; Scardino, E; Spitaleri, G; Teresa Sandri, M; Verweij, F; Zorzino, L	1
Birgegård, G; Engström-Laurent, A; Hultdin, M; Lundström, B; Samuelsson, J; Sundström, G; Wahlin, A	1
Davies, A; Gandara, D; Ho, C; Mack, P	1
Carrión, RP; Gracián, AC; Hernandez, PS	1
Colantuoni, G; Del Gaizo, F; Ferrara, C; Galetta, D; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A	1
Ahuja, A; Chan, AT; Hui, EP; Kam, M; King, A; Leung, SF; Lo, YM; Ma, B; Mo, F; Mok, T; To, KF; Zee, B	1
Capanu, M; Duffy, A; Kelsen, DP; Kortmansky, J; Minsky, B; O'Reilly, EM; Puleio, S; Saltz, L; Schwartz, GK	1
Ferretti, G; Labianca, R; Mandalà, M; Moro, C	1
Endo, K; Hisada, T; Ishizuka, T; Kaira, K; Mori, M; Oriuchi, N; Sunaga, N; Tomizawa, Y; Yanagitani, N	1
Bélanger, K; Eisenhauer, EA; Lee, CW; Petrella, TM; Rao, SC; Savage, KJ; Seymour, L; Synold, TW; Tozer, RG; Wainman, N; Wood, L	1
Chen, CS; Chen, Y; Choong, LY; Druker, BJ; Hande, MP; Lim, S; Lim, YP; Loh, MC; Man, X; Pan, M; Poonepalli, A; Salto-Tellez, M; Shah, N; Tan, PH; Toy, W; Wong, CY	1
Briasoulis, E; Georgoulias, V; Kalikaki, A; Koutsopoulos, A; Mavroudis, D; Murray, S; Pallis, AG; Souglakos, J; Stathopoulos, E; Tripaki, M; Voutsina, A	1
Chen, EX; Chia, S; Colevas, AD; Hotte, SJ; Johnson, C; Pond, GR; Schwarz, JK; Siu, LL; Synold, TW; Tang, PA; Vasist, LS; Winquist, E	1
Fregoni, V; Pavesi, L; Ponchio, L; Prada, GA; Sagrada, P; Zambelli, A	1
Chu, DT; Wang, B; Zhang, XR	1
Dibbley, SK; Lonardo, F; Piechocki, MP; Yoo, GH	1
Betticher, DC; Bihl, M; Bubendorf, L; D'Addario, G; Jost, L; Lerch, S; Mach, N; Mayer, M; Pless, M; Rauch, D; Ribi, K; Stahel, R; Stupp, R; Tapia, C; Widmer, L	1
Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P	1
Biagi, JJ; Cripps, C; Eisenhauer, E; Feld, R; Gill, S; Knox, JJ; Major, P; Seymour, L; Synold, TW; Wainman, N	1
Albert, D; Axelrod, R; Botkin, D; Dowlati, A; Lilenbaum, R; Seigel, L; Thomas, S; Witt, K	1
Ebi, N; Fukuoka, J; Fukuoka, M; Hirashima, T; Ichinose, Y; Kashii, T; Katakami, N; Kudoh, S; Negoro, S; Nishimura, T; Okamoto, I; Satoh, T; Sawa, T; Shibata, K; Shimizu, E; Tamura, K	1
Costa, DB; Kobayashi, S; Schumer, ST; Tenen, DG	1
Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ	1
Adam, P; Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Quinkler, M; Ritte, C; Ritter, C; Strasburger, C; Wortmann, S	1
Chin, TM; Chuah, KL; Lim, SW; Nga, ME; Seah, SB; Soo, RA; Soong, R; Wong, AS	1
Shih, JY; Wu, SG; Yang, PC; Yu, CJ	1
Aluri, L; Bissonnette, M; Cerda, S; Chumsangsri, A; Cohen, EE; Delgado, J; Dougherty, U; Fichera, A; Hart, J; Jagadeeswaran, S; Joseph, L; Little, N; Mustafi, R; Sehdev, A; Tretiakova, M; Yuan, W	1
Amato, RJ; Hernandez-McClain, J; Jac, J	1
Hamburger, AW	1
Hainsworth, JD; Lin, M; O'Neill, V; Spigel, DR	1
Blay, JY; Bui, BN; Hogendoorn, P; Le Cesne, A; Marreaud, S; Ray-Coquard, I; Schoffski, P; van Glabbeke, M; Verweij, J; Whelan, JS	1
Bertalanffy, A; Dieckmann, K; Dietrich, W; Gelpi, E; Hainfellner, JA; Marosi, C; Prayer, D; Preusser, M; Rottenfusser, A; Widhalm, G	1
Cobleigh, MA; Dickler, MN; Klein, PM; Miller, KD; Winer, EP	1
Adenis, A; Azab, M; Cunningham, D; Francois, E; Green, M; Iveson, A; Schornagel, J; Seymour, I; Van Cutsem, E; Zalcberg, JR	1
Jardin, A; Leplège, A; Lukacs, B; Thibault, P	1
Adenis, A; Basser, R; Drings, P; Le Chevalier, T; Perez Manga, G; Seymour, L; Smith, F; Thatcher, N; Woll, PJ	1
Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G	1
Feldman, EL; Greene, DA; Stevens, MJ	1
Silverstein, MN; Tefferi, A	1
Comet, D; Grange, JC; Lukacs, B; McCarthy, C	1
Ciardiello, F	1
Delouvée, A; el-Marjou, A; Radvanyi, F; Thiery, JP	1
Briere, J; Guilmin, F	1
Artigue, F; Buffet, C; Cassan, P; Flamenbaum, M; Garcia, V; Kemeny, JL	1
Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H	1
Arteaga, CL; Johnson, DH	1
Evans, TR; Fullarton, GM; Garcia-Vargas, J; Harris, AL; Lofts, FJ; Mackay, HJ; McDonald, AC; McInnes, A; Paul, J; Raby, N; Soukop, M	1
Barak, V; Eshhar, Z; Gavish, Z; Nagler, A; Pines, M; Pinthus, JH; Ramon, J	1
Aparicio, J; Camps, C; Escudero, P; Feliu, J; García Girón, C; González Barón, M; Mel, JR; Menéndez, D; Rodriguez, MR; Sánchez, JJ	1
Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Crucitta, E; De Lucia, L; De Vita, F; Del Prete, S; Lorusso, V; Orditura, M; Palmeri, S	1

Reviews

71 review(s) available for quinazolines and Disease Exacerbation

Article	Year
Bulletin du cancer, 2021, Volume: 108, Issue:11S Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cranial Irradiation; Disease Progression; Female; Humans; Lapatinib; Life Expectancy; Magnetic Resonance Imaging; Metastasectomy; Middle Aged; Oxazoles; Pyridines; Quinazolines; Quinolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab	2021
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? International journal of colorectal disease, 2020, Volume: 35, Issue:2 Topics: Antineoplastic Agents; Benzofurans; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Network Meta-Analysis; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Thymine; Time Factors; Trifluridine; Uracil	2020
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2017, Volume: 65, Issue:5 Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome	2017
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. Journal of the National Cancer Institute, 2017, 06-01, Volume: 109, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Sequence Deletion	2017
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. Tumori, 2017, Jul-31, Volume: 103, Issue:4 Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines	2017
Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review . International journal of clinical pharmacology and therapeutics, 2018, Volume: 56, Issue:2 Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Analysis; Time Factors; Trastuzumab; Treatment Outcome	2018
Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective. Respiratory investigation, 2018, Volume: 56, Issue:5 Topics: Asian People; Cause of Death; Disease Progression; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Japan; Lung Neoplasms; Male; Pneumonectomy; Prevalence; Prognosis; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Survival Rate	2018
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients. Journal of cellular physiology, 2019, Volume: 234, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic	2019
Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies. Cells, 2019, 01-09, Volume: 8, Issue:1 Topics: Acrylamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Progression; Fibroblast Growth Factors; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Molecular Targeted Therapy; Neoplasms; Quinazolines; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction	2019
[Treatment of essential thrombocythemia]. Medicina clinica, 2013, Sep-21, Volume: 141, Issue:6 Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progression; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Intraoperative Complications; Janus Kinase 2; Leukemia, Myeloid, Acute; Life Expectancy; Male; Middle Aged; Mutation, Missense; Platelet Aggregation Inhibitors; Point Mutation; Pregnancy; Pregnancy Complications, Hematologic; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombophilia	2013
[Lung adenocarcinoma with intramedullary spinal cord metastasis: a case report and review of the literature]. Revue de pneumologie clinique, 2013, Volume: 69, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Disease Progression; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Quinazolines; Radiography; Spinal Cord Neoplasms	2013
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. Endocrine, 2013, Volume: 44, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Drugs, Investigational; Humans; Medical Oncology; Piperidines; Professional Practice; Quinazolines; Thyroid Neoplasms; Treatment Outcome	2013
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hospital practice (1995), 2013, Volume: 41, Issue:2 Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2013
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2013 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Cell Hypoxia; Clinical Trials as Topic; Disease Progression; Drug Antagonism; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Biological; Myeloid Cells; Neoplasm Proteins; Neovascularization, Pathologic; Patient Selection; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Tumor Microenvironment; Vascular Endothelial Growth Factors	2013
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression; GPI-Linked Proteins; Hemorrhage; Humans; Hydroxyurea; Incidence; Infant; Isoantigens; Janus Kinase 2; Leukemia, Myeloid, Acute; Platelet Aggregation Inhibitors; Point Mutation; Primary Myelofibrosis; Quinazolines; Receptors, Cell Surface; Risk Assessment; Symptom Assessment; Thrombocythemia, Essential; Thrombophilia	2013
Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. The oncologist, 2014, Volume: 19, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2014
[Afatinib (BIBW 2992)]. Revue de pneumologie clinique, 2014, Volume: 70, Issue:5 Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Approval; ErbB Receptors; France; Humans; Lung Neoplasms; Quinazolines	2014
Vandetanib as a potential treatment for breast cancer. Expert opinion on investigational drugs, 2014, Volume: 23, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Quinazolines	2014
Analysis of different HER-2 mutations in breast cancer progression and drug resistance. Journal of cellular and molecular medicine, 2015, Volume: 19, Issue:12 Topics: Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mutation; Quinazolines; Receptor, ErbB-2; Trastuzumab	2015
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:2 Topics: Bone Marrow; Combined Modality Therapy; Disease Progression; Female; Fibrosis; Humans; Hydroxyurea; Janus Kinase 2; Leukapheresis; Middle Aged; Myeloproliferative Disorders; Nitriles; Phlebotomy; Point Mutation; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Splenectomy; Splenomegaly	2015
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. Journal of clinical pharmacy and therapeutics, 2015, Volume: 40, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking	2015
Management of advanced medullary thyroid cancer. The lancet. Diabetes & endocrinology, 2016, Volume: 4, Issue:1 Topics: Anilides; Antineoplastic Agents; Biomarkers; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Humans; Molecular Targeted Therapy; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Treatment Outcome	2016
Molecular Understanding of the Acquisition of Resistance to Anti-cancer Drugs Associated with the Exacerbation of Cancer. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2016, Volume: 136, Issue:5 Topics: Adenosine Triphosphate; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein-Tyrosine Kinases; Quinazolines; Receptor Cross-Talk; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled	2016
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. Expert review of anticancer therapy, 2016, Volume: 16, Issue:11 Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Child; Disease Progression; Disease-Free Survival; Humans; Piperidines; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Thyroid Neoplasms	2016
[Oncology 2008]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:25-26 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Combined Modality Therapy; Disease Progression; Epothilones; Humans; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate	2008
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. Nature clinical practice. Oncology, 2008, Volume: 5, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab	2008
[Targeted therapy for locally advanced and/or metastatic bladder cancer]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18, Issue:7 Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms	2008
Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab. Clinical breast cancer, 2008, Volume: 8 Suppl 3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab	2008
Watchful waiting in benign prostatic hyperplasia. Current opinion in urology, 2009, Volume: 19, Issue:1 Topics: Adrenergic alpha-Antagonists; Disease Progression; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Transurethral Resection of Prostate	2009
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer. Targeted oncology, 2009, Volume: 4, Issue:1 Topics: Age Factors; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome	2009
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:5 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden	2009
New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer. Clinical lung cancer, 2008, Volume: 9 Suppl 3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A	2008
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines	2010
Pathogenesis and management of essential thrombocythemia. Hematology. American Society of Hematology. Education Program, 2009 Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Leukemia, Myeloid; Middle Aged; Models, Biological; Mutation, Missense; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombophilia	2009
Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. Expert review of anticancer therapy, 2010, Volume: 10, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab	2010
[Management of metastatic HER2-positive breast cancer: present and future]. Bulletin du cancer, 2010, Volume: 97, Issue:3 Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles	2010
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome	2010
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?]. Pneumologie (Stuttgart, Germany), 2010, Volume: 64, Issue:12 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Long-Term Care; Lung Neoplasms; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2010
Second-line treatment for non-small-cell lung cancer: one size does not fit all. Clinical lung cancer, 2010, Sep-01, Volume: 11, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Taxoids	2010
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Interactions; Epothilones; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Peripheral Nervous System Diseases; Quinazolines; Treatment Failure; Treatment Outcome; Tubulin Modulators	2010
[SRC kinases in tumor therapy]. Medizinische Klinik (Munich, Germany : 1983), 2010, Volume: 105, Issue:10 Topics: Aniline Compounds; Benzodioxoles; Cell Physiological Phenomena; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; DNA Mutational Analysis; Drug Delivery Systems; Enzyme Activation; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles	2010
Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question. Cancer treatment reviews, 2010, Volume: 36 Suppl 3 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Vascular Endothelial Growth Factor A	2010
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer. Endocrine journal, 2011, Volume: 58, Issue:3 Topics: Anilides; Benzenesulfonates; Disease Progression; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Thyroid Neoplasms	2011
[Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies]. Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:4 Pt 1 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pneumonectomy; Prognosis; Protein Kinase Inhibitors; Quinazolines	2011
EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines; Radiation Tolerance	2011
Treatment of HER2-positive breast cancer: current status and future perspectives. Nature reviews. Clinical oncology, 2011, Nov-29, Volume: 9, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Disease Progression; Female; Gene Amplification; Genes, erbB-2; Heat-Shock Proteins; Humans; Lapatinib; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, IGF Type 1; Trastuzumab	2011
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). Current medical research and opinion, 2012, Volume: 28, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Lapatinib; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Triazoles	2012
[Oral antidiabetic drugs in chronic renal disease]. Orvosi hetilap, 2012, Nov-04, Volume: 153, Issue:44 Topics: Administration, Oral; Blood Glucose; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypoglycemic Agents; Linagliptin; Pioglitazone; Purines; Quinazolines; Thiazolidinediones	2012
Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nature reviews. Nephrology, 2013, Volume: 9, Issue:3 Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2013
Palliative treatment of patients with colorectal cancer. Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society, 2003, Volume: 92, Issue:1 Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Palliative Care; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Treatment Outcome; Uracil	2003
Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology, 2003, Volume: 62, Issue:3 Suppl 1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Animals; Disease Progression; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Quality of Life; Quinazolines; Rabbits; Severity of Illness Index; Transurethral Resection of Prostate; Urethral Obstruction; Urinary Retention	2003
Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor. Clinical lung cancer, 2003, Volume: 5 Suppl 1 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Ligands; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines	2003
Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention. Clinical lung cancer, 2003, Volume: 5 Suppl 1 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Quinolones	2003
Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. Surgery today, 2004, Volume: 34, Issue:4 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Molecular Biology; Neoplasms; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2004
The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Seminars in hematology, 2004, Volume: 41, Issue:2 Suppl 3 Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Disease Progression; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis	2004
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-15, Volume: 10, Issue:12 Pt 2 Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome	2004
The role of gefitinib in lung cancer treatment. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-15, Volume: 10, Issue:12 Pt 2 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis	2004
The epidermal growth factor receptor as a target for colorectal cancer therapy. Seminars in oncology, 2005, Volume: 32, Issue:1 Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction	2005
Second-line chemotherapy and beyond for non-small-cell lung cancer. Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Forecasting; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Pneumonectomy; Quinazolines; Salvage Therapy; Survival Rate; Taxoids; Time Factors	2004
The natural history of benign prostatic hyperplasia. BJU international, 2006, Volume: 97 Suppl 2 Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Disease Progression; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Retention	2006
Definition of at-risk patients: dynamic variables. BJU international, 2006, Volume: 97 Suppl 2 Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Disease Progression; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination	2006
[Palliative chemotherapy of head and neck cancer: present status and future development]. Laryngo- rhino- otologie, 2006, Volume: 85, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; ErbB Receptors; Forecasting; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine	2006
A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Current medical research and opinion, 2006, Volume: 22, Issue:3 Topics: Antineoplastic Agents; Asia; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis	2006
Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer. Clinical lung cancer, 2007, Volume: 8, Issue:7 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction	2007
Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer. Clinical lung cancer, 2007, Volume: 8, Issue:7 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Karnofsky Performance Status; Lung Neoplasms; Quinazolines; Treatment Outcome	2007
The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. Journal of mammary gland biology and neoplasia, 2008, Volume: 13, Issue:2 Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Gefitinib; Humans; Membrane Glycoproteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; RNA-Binding Proteins; Tamoxifen; Ubiquitin-Protein Ligases	2008
Diabetic neuropathy: scope of the syndrome. The American journal of medicine, 1999, Aug-30, Volume: 107, Issue:2B Topics: Aldehyde Reductase; Animals; Chronic Disease; Controlled Clinical Trials as Topic; Diabetic Foot; Diabetic Neuropathies; Disease Progression; Enzyme Inhibitors; Humans; Neural Conduction; Prevalence; Quinazolines; Syndrome	1999
Treatment of polycythaemia vera and essential thrombocythaemia. Bailliere's clinical haematology, 1998, Volume: 11, Issue:4 Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Phlebotomy; Phosphorus Radioisotopes; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocythemia, Essential; Thrombosis	1998
Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs, 2000, Volume: 60 Suppl 1 Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Gefitinib; Humans; Ligands; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Transforming Growth Factor alpha	2000
Management of patients with essential thrombocythemia: current concepts and perspectives. Pathologie-biologie, 2001, Volume: 49, Issue:2 Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Progression; Female; Hemorrhagic Disorders; Humans; Hydroxyurea; Interferons; Leukemia; Male; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Prospective Studies; Quinazolines; Risk; Safety; Thrombocythemia, Essential; Thrombophilia	2001
Tyrosine kinase inhibitors-ZD1839 (Iressa). Current opinion in oncology, 2001, Volume: 13, Issue:6 Topics: Animals; Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials as Topic; Disease Progression; Dogs; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Neoplasms; Quinazolines; Rats	2001

Trials

198 trial(s) available for quinazolines and Disease Exacerbation

Article	Year
Phase 3 Trial of Selpercatinib in Advanced The New England journal of medicine, 2023, Nov-16, Volume: 389, Issue:20 Topics: Antineoplastic Agents; Disease Progression; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms	2023
Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185). Thoracic cancer, 2020, Volume: 11, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Pyridines; Quinazolines; Research Design; Young Adult	2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 08-10, Volume: 38, Issue:23 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Double-Blind Method; Female; Humans; Middle Aged; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult	2020
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613. Clinical lung cancer, 2017, Volume: 18, Issue:5 Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Substitution; ErbB Receptors; Feasibility Studies; Gefitinib; Humans; Liquid Biopsy; Lung Neoplasms; Mutation; Piperazines; Quinazolines; Research Design; Response Evaluation Criteria in Solid Tumors	2017
Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation. AJNR. American journal of neuroradiology, 2017, Volume: 38, Issue:6 Topics: Antineoplastic Agents; Brain Stem; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dexamethasone; Diffusion Tensor Imaging; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Piperidines; Prospective Studies; Quinazolines; Steroids; Vascular Endothelial Growth Factor A; White Matter	2017
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 108 Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Monitoring; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retreatment; Sirolimus; Treatment Outcome	2017
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Journal of neuro-oncology, 2017, Volume: 134, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome	2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 113 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cohort Studies; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines	2017
Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British journal of clinical pharmacology, 2019, Volume: 85, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Drug Monitoring; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Quinazolines; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult	2019
MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma. AJNR. American journal of neuroradiology, 2013, Volume: 34, Issue:7 Topics: Adolescent; Antineoplastic Agents; Blood Volume; Brain Stem Neoplasms; Child; Child, Preschool; Cohort Studies; Disease Progression; Echo-Planar Imaging; Female; Follow-Up Studies; Glioma; Humans; Image Enhancement; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Neuroimaging; Piperidines; Prospective Studies; Quinazolines; Radiotherapy, Conformal; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Treatment Outcome	2013
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:6 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Time Factors; Treatment Outcome	2013
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 81, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Quinazolines	2013
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Xenograft Model Antitumor Assays	2013
Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer, 2013, Aug-01, Volume: 119, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines	2013
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-20, Volume: 31, Issue:27 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines	2013
Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. Journal of neuro-oncology, 2013, Volume: 115, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2013
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:15 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Proportional Hazards Models; Quinazolines	2013
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World journal of gastroenterology, 2013, Jul-28, Volume: 19, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Patient Selection; Proportional Hazards Models; Prospective Studies; Quinazolines; Time Factors; Treatment Outcome	2013
[Effectiveness of combined systemic and regional chemotherapy in treating patients with metastatic colorectal cancer after extrahepatic progression of the disease]. Voprosy onkologii, 2013, Volume: 59, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Disease Progression; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Quinazolines; Thiophenes; Treatment Outcome	2013
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Disease Progression; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pyrazoles; Quinazolines; Sulfonamides	2014
A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. Clinical lung cancer, 2014, Volume: 15, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Survival Rate	2014
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. British journal of cancer, 2013, Nov-26, Volume: 109, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C19; Disease Progression; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines	2013
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:2 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome	2014
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. British journal of cancer, 2014, Jan-07, Volume: 110, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; White People; Young Adult	2014
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. The oncologist, 2014, Volume: 19, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult	2014
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:3 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2014
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Survival Analysis; Young Adult	2014
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. The Lancet. Oncology, 2014, Volume: 15, Issue:2 Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Risk Factors; Thailand; Time Factors; Treatment Outcome	2014
A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion. Targeted oncology, 2014, Volume: 9, Issue:4 Topics: Administration, Oral; Aged; Antineoplastic Agents; Ascites; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Palliative Care; Paracentesis; Pleural Effusion; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1	2014
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 84, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Quinazolines; Treatment Outcome; Vorinostat	2014
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate	2014
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. Oncology research, 2013, Volume: 21, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Treatment Outcome	2013
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Furans; Humans; Ketones; Lung Neoplasms; Male; Middle Aged; Quinazolines	2014
MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial. Clinical advances in hematology & oncology : H&O, 2014, Volume: 12, Issue:1 Suppl 1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Genes, erbB-1; Genes, ras; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins	2014
SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Prognosis; Quinazolines; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta; Treatment Outcome	2014
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. The Lancet. Oncology, 2014, Volume: 15, Issue:8 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Deglutition Disorders; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Eating; Esophageal Neoplasms; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Pain; Proportional Hazards Models; Quality of Life; Quinazolines; Retreatment	2014
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 85, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retreatment; Small Cell Lung Carcinoma; src-Family Kinases; Treatment Outcome	2014
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC cancer, 2014, Jun-28, Volume: 14 Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Protocols; Disease Progression; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck	2014
First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Monitoring; Drug Screening Assays, Antitumor; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Quinazolines	2014
Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer, 2014, Dec-15, Volume: 120, Issue:24 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2014
All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study. Journal of the Egyptian National Cancer Institute, 2014, Volume: 26, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2014
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Dec-01, Volume: 32, Issue:34 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Colorado; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Risk Factors; Texas; Time Factors; Treatment Outcome	2014
Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib. Clinica chimica acta; international journal of clinical chemistry, 2015, Feb-02, Volume: 440 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Monitoring; Electrophoresis, Polyacrylamide Gel; Female; Humans; Immunity, Humoral; Inflammation; Lung Neoplasms; Male; Middle Aged; Precision Medicine; Quinazolines; Time Factors	2015
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2015
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Gene Dosage; Germany; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Time Factors; Treatment Outcome	2015
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-20, Volume: 33, Issue:15 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Molecular Chaperones; Mutation; Quinazolines; Resorcinols; Treatment Outcome	2015
Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial. Trials, 2015, Apr-10, Volume: 16 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; Clinical Protocols; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drugs, Chinese Herbal; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Research Design; Surveys and Questionnaires; Time Factors; Treatment Outcome; Young Adult	2015
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer, 2015, Aug-01, Volume: 121, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Quinazolines; Retrospective Studies; Time-to-Treatment; Treatment Failure	2015
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese journal of clinical oncology, 2015, Volume: 45, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Sequence Deletion; Tomography, X-Ray Computed; Treatment Outcome	2015
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. International journal of radiation oncology, biology, physics, 2015, Jun-01, Volume: 92, Issue:2 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors	2015
A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. Lung cancer (Amsterdam, Netherlands), 2015, Volume: 89, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzodioxoles; Carcinoma; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Humans; Male; Middle Aged; Quinazolines; Radiography; Response Evaluation Criteria in Solid Tumors; src-Family Kinases; Survival Rate; Thymoma; Thymus Neoplasms; Treatment Failure; Young Adult	2015
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transition Urologia internationalis, 2016, Volume: 96, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium	2016
Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. PloS one, 2015, Volume: 10, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Count; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Postmenopause; Premenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome	2015
[Oligoprogression]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2015, Volume: 191, Issue:5 Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Retreatment; Survival Rate; Treatment Failure	2015
QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific reports, 2015, Jul-03, Volume: 5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Proportional Hazards Models; Quality of Life; Quinazolines; Treatment Outcome; Young Adult	2015
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:8 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome; Tumor Burden	2015
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. The Lancet. Oncology, 2015, Volume: 16, Issue:8 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Europe; Female; Gefitinib; Genetic Predisposition to Disease; Glutamates; Guanine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2015
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2015
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer, 2015, Nov-01, Volume: 121, Issue:21 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Everolimus; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Receptors, Androgen; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome	2015
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Treatment Outcome; United Kingdom	2015
Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial. Oncotarget, 2015, Oct-06, Volume: 6, Issue:30 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Fluorouracil; Humans; Italy; Kaplan-Meier Estimate; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Quinazolines; Rectal Neoplasms; Risk Factors; Thiophenes; Time Factors; Treatment Outcome	2015
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Investigational new drugs, 2015, Volume: 33, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Lapatinib; Middle Aged; Quinazolines	2015
Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016, Volume: 16, Issue:1 Topics: Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Quinazolines; Quinazolinones	2016
Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study. Oncotarget, 2015, Nov-10, Volume: 6, Issue:35 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; China; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagoscopy; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2015
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 tr The Lancet. Oncology, 2015, Volume: 16, Issue:16 Topics: Adult; Afatinib; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Canada; Disease Progression; Disease-Free Survival; Europe; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine	2015
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study). Clinical breast cancer, 2016, Volume: 16, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine; Young Adult	2016
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:3 Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines	2016
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. Cancer imaging : the official publication of the International Cancer Imaging Society, 2016, Mar-16, Volume: 16 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Contrast Media; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, Spiral Computed; Tumor Burden; Young Adult	2016
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma. PloS one, 2016, Volume: 11, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Placebos; Quality of Life; Quinazolines; Recurrence; Safety; Vascular Endothelial Growth Factor A	2016
A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. Molecular cancer therapeutics, 2016, Volume: 15, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Disease Progression; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Neoplasm Staging; Polymorphism, Single Nucleotide; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Treatment Outcome	2016
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2016, Volume: 99 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Retreatment; Treatment Outcome	2016
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113. Cancer, 2017, 01-01, Volume: 123, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Piperidines; Quinazolines; Small Cell Lung Carcinoma	2017
Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression. Oncology research and treatment, 2016, Volume: 39, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prevalence; Quinazolines; Risk Factors; Russia; Treatment Outcome	2016
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jun-15, Volume: 14, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Ethnicity; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Time Factors; Treatment Outcome	2008
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jun-15, Volume: 14, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Erlotinib Hydrochloride; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Quinazolines; Survival Analysis; Treatment Outcome	2008
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. British journal of cancer, 2008, Sep-02, Volume: 99, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Recurrence; Survival Analysis	2008
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-10, Volume: 26, Issue:26 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Survival Analysis; Vinblastine; Vinorelbine	2008
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. The oncologist, 2008, Volume: 13, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Approval; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; United States; United States Food and Drug Administration; Young Adult	2008
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-20, Volume: 26, Issue:33 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A	2008
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Radiotherapy; Temozolomide; Treatment Outcome	2008
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Failure; Treatment Outcome	2009
A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer, 2009, Jul-01, Volume: 115, Issue:13 Topics: Administration, Oral; Adult; Aged; Carcinoma, Transitional Cell; Disease Progression; Female; Humans; Lapatinib; Male; Middle Aged; Platinum Compounds; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms	2009
Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:2 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Disease Progression; DNA Mutational Analysis; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Transcription Factors	2010
Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology (Carlton, Vic.), 2009, Volume: 14, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Transforming Growth Factor alpha; Treatment Outcome; Vascular Endothelial Growth Factor A	2009
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Sep-15, Volume: 15, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Rate	2009
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. British journal of cancer, 2009, Nov-17, Volume: 101, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Female; Humans; Japan; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Young Adult	2009
Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis	2010
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 69, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Neoplasm Recurrence, Local; Precision Medicine; Predictive Value of Tests; Proteome; Quinazolines	2010
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2010
[Efficacy and safety of Erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:2 Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate	2010
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Time Factors; Tissue Distribution; Treatment Outcome	2010
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Sep-15, Volume: 16, Issue:18 Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Gefitinib; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Pilot Projects; Prognosis; Quinazolines; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden	2010
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR. American journal of roentgenology, 2010, Volume: 195, Issue:3 Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome	2010
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-01, Volume: 16, Issue:19 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzodioxoles; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enzyme Activation; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Treatment Outcome; Young Adult	2010
Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. The Korean journal of internal medicine, 2010, Volume: 25, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies	2010
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Europe; Female; Humans; Infusions, Intravenous; Logistic Models; Middle Aged; Patient Selection; Piperidines; Placebos; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; South Africa; Taiwan; Taxoids; Time Factors; Treatment Outcome	2012
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival; Treatment Outcome	2011
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Nov-01, Volume: 16, Issue:21 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Likelihood Functions; Ovarian Neoplasms; Platinum Compounds; Prognosis; Quinazolines; Treatment Outcome; Tumor Microenvironment; Up-Regulation; Vascular Endothelial Growth Factor A	2010
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Canada; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Treatment Outcome; Tumor Burden	2012
Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Male; Middle Aged; Piperazines; Prostatic Neoplasms; Quinazolines; Receptors, Platelet-Derived Growth Factor; Survival Rate	2011
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. American journal of clinical oncology, 2012, Volume: 35, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate	2012
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-15, Volume: 17, Issue:10 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Survival Analysis; Thymidine	2011
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Quinazolines	2011
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chinese journal of cancer, 2011, Volume: 30, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Exanthema; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Remission Induction	2011
Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial. Journal of biomedicine & biotechnology, 2011, Volume: 2011 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Demography; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Quinazolines; Radiography; Radionuclide Imaging; Smoking; Time Factors; Treatment Outcome	2011
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. Clinical colorectal cancer, 2011, Mar-01, Volume: 10, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Fluorouracil; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Quinazolines	2011
Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Clinical lung cancer, 2011, Volume: 12, Issue:6 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome	2011
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. British journal of cancer, 2011, Aug-23, Volume: 105, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Disease Progression; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Squamous Cell; Placebos; Quinazolines; Single-Blind Method; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2011
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP British journal of cancer, 2011, Oct-11, Volume: 105, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids	2011
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome	2012
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-10, Volume: 30, Issue:2 Topics: Carcinoma, Neuroendocrine; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Placebos; Quinazolines; Thyroid Neoplasms	2012
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011, Volume: 52, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2011
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer research, 2012, Jan-15, Volume: 72, Issue:2 Topics: Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Disease-Free Survival; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate	2012
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-10, Volume: 30, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Piperidines; Platinum Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Risk Factors; Taxoids; Treatment Failure; Urologic Neoplasms; Urothelium	2012
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. The Lancet. Oncology, 2012, Volume: 13, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines	2012
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure	2012
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC Lung cancer (Amsterdam, Netherlands), 2012, Volume: 77, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Treatment Outcome	2012
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast cancer research and treatment, 2012, Volume: 133, Issue:3 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2012
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer, 2012, Dec-15, Volume: 118, Issue:24 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate	2012
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Aug-20, Volume: 30, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines	2012
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504). BMC cancer, 2012, Jul-20, Volume: 12 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids	2012
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung cancer (Amsterdam, Netherlands), 2012, Volume: 78, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; ras Proteins; Treatment Outcome	2012
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Po Clinical lung cancer, 2012, Volume: 13, Issue:6 Topics: Adult; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design; Survival Analysis	2012
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib	2013
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro-oncology, 2013, Volume: 15, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution	2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Investigational new drugs, 2013, Volume: 31, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Contrast Media; Demography; Disease Progression; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome	2013
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Skin; Treatment Outcome	2002
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jan-15, Volume: 21, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Mesothelioma; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome	2003
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet (London, England), 2003, Feb-08, Volume: 361, Issue:9356 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusion Pumps; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Staging; Palliative Care; Quinazolines; Survival Analysis; Thiophenes	2003
Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Thiophenes; Treatment Outcome; Vomiting	2003
Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie, 2003, Volume: 26, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Retreatment; Salvage Therapy; Stomach Neoplasms; Survival Rate; Thiophenes	2003
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:7 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome	2003
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-15, Volume: 21, Issue:14 Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Preoperative Care; Probability; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome	2003
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. British journal of cancer, 2003, Oct-20, Volume: 89, Issue:8 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome	2003
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines	2004
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study. British journal of cancer, 2004, Apr-19, Volume: 90, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome	2004
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung cancer (Amsterdam, Netherlands), 2004, Volume: 44, Issue:2 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Epidermal Growth Factor; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Survival Analysis	2004
Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:5 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis	2004
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Interactions; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Treatment Outcome	2004
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute, 2004, Aug-04, Volume: 96, Issue:15 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Enzyme Inhibitors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Staging; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Analysis; Treatment Outcome	2004
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. International journal of cancer, 2005, Jan-01, Volume: 113, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Analysis	2005
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3 Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines	2005
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast cancer research and treatment, 2005, Volume: 89, Issue:2 Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Survival Analysis; Taxoids; Treatment Outcome	2005
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-15, Volume: 11, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Survival Rate; Treatment Outcome	2005
Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-15, Volume: 11, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Skin Diseases; Smoking; Survival Analysis; Treatment Outcome	2005
Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 50, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Dyspnea; Female; Follow-Up Studies; Gefitinib; Health Status; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Function Tests; Retrospective Studies; Sex Factors; Survival Analysis; Treatment Outcome	2005
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-01, Volume: 23, Issue:25 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Protein Kinase Inhibitors; Quinazolines; Survival Analysis	2005
Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer. Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Constipation; Disease Progression; Dyspnea; Fatigue; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Survival Analysis; Treatment Outcome	2005
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Nov-01, Volume: 11, Issue:21 Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Clinical Trials as Topic; Cluster Analysis; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Genome; Glioma; Humans; Lung Neoplasms; Models, Biological; Mutation; Nucleic Acid Hybridization; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Time Factors	2005
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis	2005
Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. British journal of cancer, 2006, Mar-13, Volume: 94, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Quinazolines; Survival Analysis	2006
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Salvage Therapy; Survival Analysis; Thiophenes	2006
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU international, 2006, Volume: 97, Issue:4 Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Risk Factors; Treatment Outcome; Urinary Retention	2006
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. Future oncology (London, England), 2006, Volume: 2, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival; Treatment Outcome; Up-Regulation	2006
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. British journal of cancer, 2006, Apr-24, Volume: 94, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Recurrence; Risk Factors; Signal Transduction; Survival Rate; Treatment Outcome	2006
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. British journal of cancer, 2006, Jun-05, Volume: 94, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Taxoids; Treatment Outcome	2006
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jun-01, Volume: 12, Issue:11 Pt 1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pyrazoles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Treatment Outcome	2006
Phase II study of erlotinib in patients with advanced biliary cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-01, Volume: 24, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Biliary Tract Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis	2006
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-01, Volume: 12, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Predictive Value of Tests; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Deletion; Survival Rate; Treatment Outcome	2006
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer, 2006, Sep-01, Volume: 107, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2006
The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer--a phase II study. Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mitomycin; Quality of Life; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome	2006
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. British journal of cancer, 2006, Oct-23, Volume: 95, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pruritus; Quinazolines; Treatment Outcome	2006
The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. European radiology, 2007, Volume: 17, Issue:7 Topics: Administration, Oral; Adult; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Contrast Media; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gefitinib; Humans; Image Processing, Computer-Assisted; Injections, Intravenous; Liver Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Pancreatic Neoplasms; Pelvic Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Tomography, Spiral Computed	2007
Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer. BMC cancer, 2006, Dec-16, Volume: 6 Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Quinazolines; Survival Analysis	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Heart Diseases; Humans; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis	2006
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 56, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; Drug Administration Schedule; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Severity of Illness Index; Treatment Outcome	2007
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Investigational new drugs, 2007, Volume: 25, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinazolines; Taxoids; Treatment Outcome	2007
[Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease Progression; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction; Sex Factors; Treatment Outcome	2007
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-20, Volume: 25, Issue:18 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome	2007
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer, 2007, Aug-15, Volume: 110, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Disease Progression; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Patient Dropouts; Quinazolines; Time Factors; Treatment Outcome	2007
An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie, 2007, Volume: 30, Issue:7 Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Gefitinib; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Survival Rate; Taxoids; Treatment Outcome	2007
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Gefitinib; Humans; Lactones; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proteomics; Quinazolines; Sulfones; Survival Rate; Treatment Outcome	2007
Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. Anti-cancer drugs, 2007, Volume: 18, Issue:8 Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progression; Drug Resistance, Neoplasm; Endpoint Determination; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Immunohistochemistry; Male; Middle Aged; Pain Measurement; Prostatic Neoplasms; Quality of Life; Quinazolines; Surveys and Questionnaires	2007
Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Medical oncology (Northwood, London, England), 2007, Volume: 24, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Fibrinolytic Agents; Humans; Hyaluronic Acid; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Prospective Studies; Quinazolines; Reticulin; Thrombocythemia, Essential; Thrombocytosis	2007
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:1 Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; DNA, Viral; ErbB Receptors; Female; Gefitinib; Herpesvirus 4, Human; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Radiography; Survival	2008
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Treatment Outcome	2008
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Investigational new drugs, 2008, Volume: 26, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Drug Delivery Systems; Eye Neoplasms; Female; Humans; Kinesins; Male; Melanoma; Middle Aged; Mucous Membrane; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Skin Neoplasms; Treatment Outcome	2008
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Investigational new drugs, 2008, Volume: 26, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Female; Gene Expression; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Kinesins; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Quinazolines; Treatment Outcome	2008
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; Radiography; ras Proteins; Risk Assessment; Risk Factors; Smoking; Surveys and Questionnaires; Switzerland; Treatment Outcome	2008
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast cancer research and treatment, 2008, Volume: 112, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Trastuzumab	2008
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Investigational new drugs, 2008, Volume: 26, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Hepatocellular; Disease Progression; Female; Gene Expression; Humans; Infusions, Intravenous; Kinesins; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome	2008
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-20, Volume: 26, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires	2008
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). British journal of cancer, 2008, Mar-11, Volume: 98, Issue:5 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines	2008
Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:6 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Routes; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Salvage Therapy; Treatment Outcome	2008
Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial. Anti-cancer drugs, 2008, Volume: 19, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Imatinib Mesylate; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Survival Rate	2008
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer, 2008, Jun-15, Volume: 112, Issue:12 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Ethnicity; Female; Humans; In Vitro Techniques; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Sex Factors; Smoking; Survival Analysis	2008
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. The oncologist, 2008, Volume: 13, Issue:4 Topics: Adult; Aged; Antibiotics, Antineoplastic; Biomarkers, Tumor; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sarcoma, Synovial; Treatment Failure; Treatment Outcome	2008
Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. Journal of neuro-oncology, 2008, Volume: 89, Issue:2 Topics: Adult; Aged; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Secondary Prevention	2008
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast cancer research and treatment, 2009, Volume: 115, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Taxoids	2009
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Humans; Male; Middle Aged; Quinazolines; Remission Induction; Survival Analysis; Thiophenes; Thymidylate Synthase	1996
Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology, 1996, Volume: 48, Issue:5 Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Family Practice; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexuality; Surveys and Questionnaires; Time Factors; Treatment Failure	1996
Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer. British journal of cancer, 1997, Volume: 76, Issue:2 Topics: Adult; Aged; Carcinoma, Small Cell; Disease Progression; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome	1997
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Quality of Life; Quinazolines; Survival Analysis; Thiophenes	1998
History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. European urology, 2000, Volume: 37, Issue:2 Topics: Adrenergic alpha-Antagonists; Aged; Cohort Studies; Disease Progression; Family Practice; Follow-Up Studies; Humans; Male; Prostatic Hyperplasia; Quinazolines; Time Factors; Urinary Retention	2000
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome	2001
A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Hypersensitivity; Enteritis; Epirubicin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pulmonary Embolism; Quinazolines; Sepsis; Stomach Neoplasms; Survival Analysis; Thiophenes; Treatment Outcome	2001
Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:9 Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Quinazolines; Sex Factors; Survival Analysis; Thiophenes; Treatment Outcome	2002
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. British journal of cancer, 2002, Jun-17, Volume: 86, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome	2002

Other Studies

236 other study(ies) available for quinazolines and Disease Exacerbation

Article	Year
Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 145 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Disease Progression; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Phenylenediamines; Quinazolines; Survivin; Xenograft Model Antitumor Assays	2022
G9a and histone deacetylases are crucial for Snail2-mediated E-cadherin repression and metastasis in hepatocellular carcinoma. Cancer science, 2019, Volume: 110, Issue:11 Topics: Acetylation; Animals; Azepines; Cadherins; Carcinoma, Hepatocellular; Cell Movement; Disease Progression; Down-Regulation; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Histocompatibility Antigens; Histone Deacetylase Inhibitors; Histone Deacetylases; Histone-Lysine N-Methyltransferase; Humans; Hydroxamic Acids; Liver; Liver Neoplasms; Methylation; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Quinazolines; Snail Family Transcription Factors; Transcription, Genetic; Transforming Growth Factor beta	2019
Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study. Cancer medicine, 2020, Volume: 9, Issue:1 Topics: Aged; Asian People; Carcinoma, Non-Small-Cell Lung; China; Circulating Tumor DNA; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies	2020
Acceleration of interstitial lung disease induced by raltitrexed. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:5 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Humans; Lung Diseases, Interstitial; Male; Quinazolines; Thiophenes	2020
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study. Cancer science, 2020, Volume: 111, Issue:2 Topics: Carcinoma, Non-Small-Cell Lung; China; Circulating Tumor DNA; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Regulatory Networks; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Sequence Analysis, DNA	2020
Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases. Asia-Pacific journal of clinical oncology, 2021, Volume: 17, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Cranial Irradiation; Crown Ethers; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Quality of Life; Quinazolines	2021
Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation. International journal of molecular sciences, 2020, Feb-05, Volume: 21, Issue:3 Topics: Apoptosis; Aurora Kinase B; Benzamides; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Imidazoles; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1; Transcription, Genetic	2020
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 08-20, Volume: 38, Issue:24 Topics: Adult; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines; Survival Analysis; Thyroid Neoplasms	2020
Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer. Biomolecules, 2020, 12-16, Volume: 10, Issue:12 Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Histones; Humans; Inhibitory Concentration 50; Lysine; Ovarian Neoplasms; Prognosis; Quinazolines; RNA, Small Interfering; Transfection; Up-Regulation	2020
Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function. Pharmacology, 2021, Volume: 106, Issue:5-6 Topics: Aged; Calreticulin; Creatinine; Disease Progression; Female; Humans; Hydroxyurea; Janus Kinase 2; Kidney Diseases; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Thrombocythemia, Essential; Treatment Outcome	2021
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. European journal of cancer (Oxford, England : 1990), 2021, Volume: 149 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; Disease Progression; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Time Factors	2021
Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study. BMC cancer, 2017, 04-04, Volume: 17, Issue:1 Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Quality of Life; Quinazolines	2017
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. The oncologist, 2017, Volume: 22, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Hepatitis C, Chronic; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Smoking; Taiwan	2017
Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation. Clinical lung cancer, 2017, Volume: 18, Issue:6 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome	2017
Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer. Anticancer research, 2017, Volume: 37, Issue:8 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Disease Progression; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MicroRNAs; Pyrazoles; Quinazolines; Quinolines; Signal Transduction; Up-Regulation	2017
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018, Volume: 20, Issue:3 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy	2018
Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report. Medicine, 2017, Volume: 96, Issue:33 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines	2017
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression. PloS one, 2017, Volume: 12, Issue:8 Topics: ADAMTS Proteins; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium-Binding Proteins; Calponins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exome; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Microfilament Proteins; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Wnt Proteins	2017
Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab. Thoracic cancer, 2018, Volume: 9, Issue:1 Topics: Afatinib; Aged; Antibodies, Monoclonal; Carcinoma, Squamous Cell; Disease Progression; Humans; Lung Neoplasms; Male; Nivolumab; Quinazolines	2018
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 02-15, Volume: 24, Issue:4 Topics: Adolescent; Carcinoma, Medullary; Child; Disease Progression; Disease-Free Survival; Female; Germ-Line Mutation; Humans; Male; Multiple Endocrine Neoplasia Type 2a; Outcome Assessment, Health Care; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms	2018
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. Future oncology (London, England), 2018, Volume: 14, Issue:15 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Program Evaluation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Failure	2018
Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment. Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:1 Topics: Adult; Aged; Alleles; Antineoplastic Agents; Carcinoma; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome	2018
Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression. Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Prospective Studies; Quinazolines; Survival Rate	2018
Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages. Cell death & disease, 2018, 06-07, Volume: 9, Issue:6 Topics: Adenine; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Class Ia Phosphatidylinositol 3-Kinase; Disease Progression; Enzyme Activation; Female; Humans; Macrophages; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Staging; PTEN Phosphohydrolase; Quinazolines	2018
Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia. Experimental hematology, 2018, Volume: 66 Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Chromones; Disease Progression; Dose-Response Relationship, Drug; Female; Flavonoids; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morpholines; Myeloid Cells; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptor, PAR-1; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A	2018
Efficacy and safety of raltitrexed-based transarterial chemoembolization for colorectal cancer liver metastases. Anti-cancer drugs, 2018, Volume: 29, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; China; Colorectal Neoplasms; Disease Progression; Ethiodized Oil; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Oxaliplatin; Prospective Studies; Quinazolines; Survival; Thiophenes	2018
EGFR inhibitor, AG1478, inhibits inflammatory infiltration and angiogenesis in mice with diabetic retinopathy. Clinical and experimental pharmacology & physiology, 2019, Volume: 46, Issue:1 Topics: Animals; Diabetic Retinopathy; Disease Progression; ErbB Receptors; Female; Inflammation; Macrophages; Male; Mice; Mitochondria; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Retinal Vessels; Tyrphostins	2019
Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. American journal of hematology, 2019, Volume: 94, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow; Disease Progression; Disease-Free Survival; Drug Approval; Female; Fibrosis; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Thrombocythemia, Essential; Thrombosis; Treatment Outcome; Young Adult	2019
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nature communications, 2019, 04-18, Volume: 10, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; G1 Phase Cell Cycle Checkpoints; Histones; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Organophosphates; Phosphorylation; Polyploidy; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays	2019
Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting. European journal of haematology, 2019, Volume: 103, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential; Treatment Outcome; Young Adult	2019
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report. BMC cancer, 2019, Jul-17, Volume: 19, Issue:1 Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Female; Follow-Up Studies; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines	2019
Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study. Journal of the Indian Medical Association, 2012, Volume: 110, Issue:7 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Quinazolines; Retreatment; Retrospective Studies; Sex Factors; Treatment Outcome	2012
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers? Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Rate	2013
EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS. PloS one, 2013, Volume: 8, Issue:4 Topics: Amyotrophic Lateral Sclerosis; Animals; Astrocytes; Biomarkers; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Longevity; Mice; Mice, Transgenic; Microglia; Motor Neurons; Neuromuscular Junction; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Spinal Cord; Staining and Labeling; Superoxide Dismutase; Superoxide Dismutase-1; Survival Analysis; Synapses; Time Factors	2013
Recurrent respiratory papillomatosis with lung involvement and malignant transformation. Thorax, 2014, Volume: 69, Issue:3 Topics: Bronchial Neoplasms; Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chemoradiotherapy, Adjuvant; Contrast Media; Disease Progression; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Tomography, X-Ray Computed; Treatment Outcome	2014
Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib. Chinese medical journal, 2013, Volume: 126, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies	2013
Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:6 Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Disease Progression; ErbB Receptors; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Mice; Myofibroblasts; Quinazolines; Signal Transduction; Stromal Cells	2013
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR. American journal of roentgenology, 2013, Volume: 201, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome	2013
Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer. Clinica chimica acta; international journal of clinical chemistry, 2013, Oct-21, Volume: 425 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA	2013
Role for the epidermal growth factor receptor in chemotherapy-induced alopecia. PloS one, 2013, Volume: 8, Issue:7 Topics: Alopecia; Animals; Antineoplastic Agents; Apoptosis; Cyclophosphamide; Disease Progression; Drug Tolerance; ErbB Receptors; Erlotinib Hydrochloride; Hair Follicle; Humans; Mice; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53	2013
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression? Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Anilides; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms	2013
Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Molecular cancer, 2013, Sep-11, Volume: 12, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Tyrphostins; Xenograft Model Antitumor Assays	2013
Combined inhibition of PDE4 and PI3Kδ modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease. Drug research, 2014, Volume: 64, Issue:4 Topics: Adenine; Aminopyridines; Benzamides; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cyclopropanes; Disease Progression; Humans; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 9; Neutrophils; Nicotiana; Phosphodiesterase 4 Inhibitors; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pulmonary Alveoli; Pulmonary Disease, Chronic Obstructive; Quinazolines; Smoke; U937 Cells	2014
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). Journal of chemotherapy (Florence, Italy), 2014, Volume: 26, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies	2014
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer. The European respiratory journal, 2014, Volume: 43, Issue:1 Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Treatment Failure; Treatment Outcome	2014
Epidermal growth factor enhances androgen receptor‑mediated bladder cancer progression and invasion via potentiation of AR transactivation. Oncology reports, 2013, Volume: 30, Issue:6 Topics: Androgens; Animals; Butylhydroxybutylnitrosamine; Carcinogenesis; Castration; Disease Models, Animal; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Humans; Male; Mice; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Quinazolines; Receptors, Androgen; Signal Transduction; Transcriptional Activation; Urinary Bladder Neoplasms	2013
Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth. Molecular cancer therapeutics, 2013, Volume: 12, Issue:12 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cluster Analysis; Disease Models, Animal; Disease Progression; Female; Humans; Mice; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; Proteomics; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Triazines; Tumor Burden; Xenograft Model Antitumor Assays	2013
Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy. Acta neuropathologica communications, 2013, Jul-17, Volume: 1 Topics: Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Progression; Down-Regulation; Erlotinib Hydrochloride; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mice; Neural Conduction; Neuregulin-1; Protein Isoforms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sural Nerve	2013
EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis. Journal of immunology (Baltimore, Md. : 1950), 2014, Feb-01, Volume: 192, Issue:3 Topics: Administration, Cutaneous; Allergens; Animals; Cells, Cultured; Chemokine CXCL1; Chemokine CXCL2; Dermatitis, Atopic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Interleukin-17; Interleukin-1beta; Interleukin-22; Interleukin-6; Interleukins; Keratinocytes; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Quinazolines; Recurrence; Signal Transduction; Skin; Specific Pathogen-Free Organisms; Th17 Cells	2014
Bayesian models for cost-effectiveness analysis in the presence of structural zero costs. Statistics in medicine, 2014, May-20, Volume: 33, Issue:11 Topics: Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Costs and Cost Analysis; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Models, Economic; Multicenter Studies as Topic; Quality-Adjusted Life Years; Quinazolines	2014
[Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines	2013
Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors. Cancer medicine, 2014, Volume: 3, Issue:1 Topics: Aged; Aged, 80 and over; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines	2014
Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-20, Volume: 32, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome	2014
Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2014
High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:7 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines	2014
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:4 Topics: Animals; Bile Ducts; Carbon Tetrachloride; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Diethylnitrosamine; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Hepatic Stellate Cells; Hepatocytes; Humans; Ligation; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred Strains; Phosphorylation; Prognosis; Quinazolines; Rats; Rats, Wistar; Transcriptome	2014
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. International journal of radiation oncology, biology, physics, 2014, Jun-01, Volume: 89, Issue:2 Topics: Adenocarcinoma; Brain Neoplasms; Cranial Irradiation; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis	2014
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 84, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines	2014
Reossification of osteolytic metastases at the acetabulum following gefitinib and multidisciplinary treatment for lung cancer: a case report with autopsy findings. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2015, Volume: 20, Issue:5 Topics: Acetabulum; Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Autopsy; Biopsy; Bone Neoplasms; Disease Progression; ErbB Receptors; Fatal Outcome; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Ossification, Heterotopic; Quinazolines; Tomography, X-Ray Computed	2015
Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes, 2014, Volume: 63, Issue:6 Topics: Albuminuria; AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Blood Glucose; Blood Pressure; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Immunohistochemistry; Kidney; Mice; Mice, Inbred NOD; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2014
P2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage. CNS neuroscience & therapeutics, 2014, Volume: 20, Issue:6 Topics: Amygdala; Animals; Animals, Newborn; Bumetanide; Cell Death; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Female; Hippocampus; Kainic Acid; Male; Purinergic P2X Receptor Antagonists; Pyridines; Quinazolines; Rats; Rats, Sprague-Dawley; Sodium Potassium Chloride Symporter Inhibitors; Status Epilepticus; Tetrazoles	2014
Erlotinib might be a double-edged sword in HCC. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:2 Topics: Animals; Carcinoma, Hepatocellular; Disease Progression; ErbB Receptors; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Quinazolines	2015
Reply: To PMID 24677197. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:2 Topics: Animals; Carcinoma, Hepatocellular; Disease Progression; ErbB Receptors; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Quinazolines	2015
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. Clinical lung cancer, 2014, Volume: 15, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Italy; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases	2014
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung cancer (Amsterdam, Netherlands), 2014, Volume: 85, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors	2014
[Gefitinib treatment in lung cancer -- rebiopsy, retreatment, remission]. Magyar onkologia, 2014, Volume: 58, Issue:2 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bronchial Neoplasms; Disease Progression; Docetaxel; ErbB Receptors; Exons; Female; Gefitinib; Gene Deletion; Genes, erbB-1; Humans; Molecular Targeted Therapy; Quinazolines; Remission Induction; Retreatment; Taxoids; Treatment Outcome	2014
EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 85, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Repetitive Sequences, Nucleic Acid; Risk Factors; Treatment Outcome	2014
Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Analysis	2014
Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1 Topics: Adult; Afatinib; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2015
HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Molecular oncology, 2015, Volume: 9, Issue:3 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Disease Progression; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; Mice, Nude; Mutant Proteins; Mutation; Phenotype; Phosphorylation; Prognosis; Protein Structure, Tertiary; Quinazolines; Treatment Outcome	2015
Inhibition of progression of PanIN through antagonizing EGFR. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:5 Topics: Animals; Antineoplastic Agents; Carcinoma in Situ; Disease Progression; Drug Screening Assays, Antitumor; ErbB Receptors; Male; Mice, Transgenic; Pancreas; Pancreatic Neoplasms; Quinazolines; Tyrphostins	2015
Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015, Volume: 17, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome	2015
Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor. Journal of clinical pathology, 2015, Volume: 68, Issue:4 Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2015
Disease flare after gefitinib discontinuation. Respiratory investigation, 2015, Volume: 53, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Withholding Treatment	2015
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature communications, 2015, Mar-11, Volume: 6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides	2015
EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy. Journal of the American Society of Nephrology : JASN, 2015, Volume: 26, Issue:11 Topics: Animals; Chemokines; Cytokines; Disease Progression; ErbB Receptors; Fibroblasts; Fibrosis; Gefitinib; Hyperuricemia; Inflammation; Kidney; Kidney Diseases; Male; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Risk Factors; Signal Transduction; Transforming Growth Factor beta; Transforming Growth Factor beta1; Uric Acid	2015
Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question. Tumori, 2015, Jul-24, Volume: 101, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed	2015
The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy. Neuromuscular disorders : NMD, 2015, Volume: 25, Issue:9 Topics: Animals; Body Weight; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Endoribonucleases; Female; Follistatin; Kaplan-Meier Estimate; Male; Mice; Mice, Transgenic; Motor Activity; Muscular Atrophy, Spinal; Quinazolines; Recombinant Proteins; Survival of Motor Neuron 1 Protein; Survival of Motor Neuron 2 Protein	2015
Reduction in disease progression by inhibition of transforming growth factor α-CCL2 signaling in experimental posttraumatic osteoarthritis. Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:10 Topics: Animals; Benzoxazines; Cartilage, Articular; Chemokine CCL2; Disease Models, Animal; Disease Progression; Male; Osteoarthritis; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Spiro Compounds; Transforming Growth Factor alpha; Tyrphostins; Up-Regulation; Wounds and Injuries	2015
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors. Oncotarget, 2015, Sep-22, Volume: 6, Issue:28 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors	2015
Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease Progression in HER2-Positive Breast Cancer. Clinical breast cancer, 2015, Volume: 15, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Salvage Therapy; Trastuzumab	2015
Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report. Future oncology (London, England), 2015, Volume: 11, Issue:15 Suppl Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Fatal Outcome; Female; Furans; Humans; Ketones; Lapatinib; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retreatment; Trastuzumab	2015
Src and epidermal growth factor receptor mediate the pro-invasive activity of Bcl-w. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Cell Line, Tumor; Cell Movement; Disease Progression; ErbB Receptors; Gefitinib; Humans; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Reactive Oxygen Species; src-Family Kinases	2016
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome. Archives of endocrinology and metabolism, 2015, Volume: 59, Issue:4 Topics: Adult; Carcinoma, Neuroendocrine; Cushing Syndrome; Disease Progression; Female; Humans; Neoplasm Staging; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome	2015
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; China; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2015
Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study. PloS one, 2015, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Israel; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab	2015
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2015, Volume: 18, Issue:6 Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Markov Chains; Models, Economic; Molecular Targeted Therapy; Mutation; Patient Selection; Pemetrexed; Protein Kinase Inhibitors; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Uncertainty; United States	2015
[An Elderly Patient with Non-Small Cell Lung Cancer Who Responded to Salvage S-1 Monotherapy after Gefitinib Therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:9 Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Combinations; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Oxonic Acid; Quinazolines; Salvage Therapy; Tegafur	2015
RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Lung cancer (Amsterdam, Netherlands), 2015, Volume: 90, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Treatment Outcome	2015
Pancreatic Tumor Progression Associated With CD133 Overexpression: Involvement of Increased TERT Expression and Epidermal Growth Factor Receptor-Dependent Akt Activation. Pancreas, 2016, Volume: 45, Issue:3 Topics: AC133 Antigen; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Telomerase; Transplantation, Heterologous	2016
Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis. Journal of the American Society of Nephrology : JASN, 2016, Volume: 27, Issue:9 Topics: Animals; Disease Progression; ErbB Receptors; Gefitinib; Male; Peritoneal Fibrosis; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Time Factors; Transforming Growth Factor beta1	2016
Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Academic radiology, 2016, Volume: 23, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Young Adult	2016
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. Journal of medical economics, 2016, Volume: 19, Issue:6 Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Disease Progression; Female; Health Services; Humans; Lapatinib; Letrozole; Markov Chains; Models, Econometric; Neoplasm Metastasis; Nitriles; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Terminal Care; Trastuzumab; Triazoles	2016
Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation. Pathology oncology research : POR, 2016, Volume: 22, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2016
Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. Nature communications, 2016, 06-21, Volume: 7 Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydroxychloroquine; Lung Neoplasms; Lymphatic Metastasis; Mice; MicroRNAs; Neoplastic Stem Cells; Oligonucleotides; Quinazolines; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays	2016
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-15, Volume: 22, Issue:20 Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Madin Darby Canine Kidney Cells; Male; Mice; Mice, SCID; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Xenograft Model Antitumor Assays	2016
Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016, Volume: 11, Issue:11 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Middle Aged; Mutation; Pilot Projects; Prospective Studies; Quinazolines; Radiation-Sensitizing Agents	2016
A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer. Oncotarget, 2016, Sep-27, Volume: 7, Issue:39 Topics: Adenovirus E1A Proteins; Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, SCID; Neoplasm Transplantation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases	2016
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. Lung cancer (Amsterdam, Netherlands), 2016, Volume: 100 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Programmed Cell Death 1 Receptor; Quinazolines; Survival Analysis; Tumor Escape	2016
EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget, 2016, Dec-20, Volume: 7, Issue:51 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Databases, Factual; Disease Progression; Disease-Free Survival; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Risk Assessment; Risk Factors; Singapore; Time Factors; Treatment Outcome	2016
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 103 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2017
Retrospective Analysis of Different Treatment Schemes After Gefitinib Resistance in Advanced Non-small Cell Lung Cancer. Clinical therapeutics, 2017, Volume: 39, Issue:3 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate	2017
[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2017, Feb-23, Volume: 39, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2017
Gefitinib single drug in treatment of advanced esophageal cancer. Journal of cancer research and therapeutics, 2016, Volume: 12, Issue:Supplement Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Esophageal Neoplasms; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2016
Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes. The New Zealand medical journal, 2017, Mar-03, Volume: 130, Issue:1451 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Financing, Government; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Audit; Middle Aged; New Zealand; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies	2017
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. International journal of cancer, 2008, Sep-01, Volume: 123, Issue:5 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Protein-Tyrosine Kinases; Quinazolines; Transplantation, Heterologous	2008
[Targeted therapy for metastatic bladder cancer]. Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Transitional Cell; Disease Progression; Drug Delivery Systems; Gefitinib; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Sorafenib; Survival Rate; Trastuzumab; Urinary Bladder Neoplasms	2008
Prolonged response to gefitinib in bone metastasis. Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Back Pain; Carboplatin; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Spinal Neoplasms; Time Factors	2009
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Cohort Studies; Disease Progression; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor; Survival Analysis	2009
Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment. Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Breast Neoplasms; Disease Progression; Epithelial Cells; Female; Gene Amplification; Humans; Lapatinib; Monitoring, Physiologic; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2009
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. Clinical breast cancer, 2008, Volume: 8, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab	2008
Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib. Archives of dermatology, 2008, Volume: 144, Issue:11 Topics: Aged; Alopecia; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Cicatrix; Disease Progression; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Quinazolines; Risk Assessment	2008
Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer. Bulletin of experimental biology and medicine, 2008, Volume: 145, Issue:2 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome	2008
[Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:6 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Salvage Therapy; Treatment Failure	2008
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung cancer (Amsterdam, Netherlands), 2009, Volume: 65, Issue:3 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Remission Induction; Smoking	2009
Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. American journal of respiratory cell and molecular biology, 2009, Volume: 41, Issue:5 Topics: Animals; Carrier Proteins; Collagen; Disease Models, Animal; Disease Progression; Doxycycline; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Lung; Mice; Mice, Transgenic; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pulmonary Fibrosis; Quinazolines; Respiratory Mechanics; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Transforming Growth Factor alpha; Uteroglobin	2009
PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovascular research, 2009, Aug-01, Volume: 83, Issue:3 Topics: Administration, Oral; Animals; Blood Pressure; Cardiovascular Agents; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Isoenzymes; JNK Mitogen-Activated Protein Kinases; Male; Myocardium; Natriuretic Peptide, Brain; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinase C; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Inbred SHR; Signal Transduction; Time Factors; Ventricular Function, Left; Ventricular Remodeling	2009
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-01, Volume: 27, Issue:22 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Immunohistochemistry; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed	2009
Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:7 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Predictive Value of Tests; Prospective Studies; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome	2009
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:2 Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Genetic Association Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-met; Quinazolines	2010
[Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials]. Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Young Adult	2009
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:3 Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome	2010
[Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months]. Revue de pneumologie clinique, 2009, Volume: 65, Issue:5 Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines	2009
Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib. Dermatology online journal, 2009, Nov-15, Volume: 15, Issue:11 Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dermatitis, Seborrheic; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Follow-Up Studies; Hand Dermatoses; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Syndrome	2009
Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer. Anticancer research, 2009, Volume: 29, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate; Time Factors	2009
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer, 2010, Mar-01, Volume: 116, Issue:5 Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Korea; Male; Protein Kinase Inhibitors; Quinazolines	2010
Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clinical & experimental metastasis, 2010, Volume: 27, Issue:1 Topics: Animals; Cell Line, Tumor; Cell Movement; Disease Progression; Humans; Melanoma; Mice; Mice, SCID; Neoplasm Metastasis; Pyrroles; Quinazolines; Receptor, PAR-1; Skin Neoplasms	2010
Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion; Predictive Value of Tests; Quinazolines; Survival Analysis	2010
Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 70, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome; Whole-Body Irradiation	2010
Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, May-01, Volume: 16, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome	2010
Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 70, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Exanthema; Female; Humans; Japan; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Quinazolines; Risk	2010
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wiener klinische Wochenschrift, 2010, Volume: 122, Issue:11-12 Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; ErbB Receptors; Europe; Evidence-Based Medicine; Female; Humans; Lapatinib; Neoplasm Staging; Neoplasms, Hormone-Dependent; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone	2010
Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland. Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Scotland; Survival Rate; Treatment Outcome	2010
Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:8 Topics: Algorithms; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Progression; Drug Evaluation, Preclinical; ErbB Receptors; Gene Expression Regulation, Neoplastic; Mice; Mice, Transgenic; Neoplasms, Glandular and Epithelial; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Skin Neoplasms; Treatment Outcome	2010
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2010, Volume: 31, Issue:7 Topics: Adolescent; Adult; Antineoplastic Agents; Audiometry, Pure-Tone; Disease Progression; Erlotinib Hydrochloride; Female; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Speech Perception; Treatment Outcome; Young Adult	2010
Toxicity manifesting as cosmetic hair alterations during erlotinib treatment. Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:1 Topics: Adenocarcinoma; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Hypertrichosis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2011
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Cancer biology & therapy, 2010, Nov-01, Volume: 10, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Genetic Markers; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab	2010
Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy. Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:11 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines	2010
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Dec-01, Volume: 16, Issue:23 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome	2010
The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:11 Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Disease Models, Animal; Disease Progression; ErbB Receptors; Fluorescent Antibody Technique; Gefitinib; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pancreatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction	2010
Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell cycle (Georgetown, Tex.), 2011, Mar-01, Volume: 10, Issue:5 Topics: Animals; Antineoplastic Agents; Cell Line; Cell Transformation, Neoplastic; Chlorocebus aethiops; Disease Progression; Female; Gefitinib; Humans; Lapatinib; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT1 Transcription Factor; Transplantation, Heterologous	2011
Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:5 Topics: Abdominal Pain; Adenocarcinoma, Papillary; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Immunohistochemistry; Lapatinib; Lymphatic Metastasis; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome	2011
Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. Oncogene, 2011, Jul-07, Volume: 30, Issue:27 Topics: Breast Neoplasms; Disease Progression; Female; Humans; Immediate-Early Proteins; Lapatinib; Quinazolines; Tumor Suppressor Proteins	2011
Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Tumor Burden	2011
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC cancer, 2011, Mar-02, Volume: 11 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines	2011
Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib. Clinical biochemistry, 2011, Volume: 44, Issue:10-11 Topics: Aged; Algorithms; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Disease Progression; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2011
Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis; Withholding Treatment	2011
Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer. Technology Evaluation Center Assessment Program. Executive summary, 2011, Volume: 25, Issue:6 Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Technology Assessment, Biomedical; Treatment Outcome	2011
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast cancer research : BCR, 2011, Jun-15, Volume: 13, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Disease Progression; ErbB Receptors; Female; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Predictive Value of Tests; Prognosis; Quinazolines; Trastuzumab	2011
[Management of patients with resistance to EGFR-TKI]. Revue de pneumologie clinique, 2011, Volume: 67 Suppl 1 Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis; Treatment Outcome	2011
Erlotinib-induced rash spares previously irradiated skin. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:8 Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy, Adjuvant; Tomography, X-Ray Computed	2011
Drug-induced effects on erlotinib metabolism. The New England journal of medicine, 2011, Jul-28, Volume: 365, Issue:4 Topics: Adenocarcinoma; Aged; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines	2011
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Oct-01, Volume: 17, Issue:19 Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Withholding Treatment	2011
Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2 Topics: Adenocarcinoma; Adult; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Pleural Effusion, Malignant; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third; Quinazolines; Remission Induction; Respiratory Insufficiency; Sequence Deletion; Term Birth	2011
Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2012
[Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2011, Volume: 14, Issue:10 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Treatment Outcome	2011
Comparison of ROCK and EGFR activation pathways in the progression of glomerular injuries in AngII-infused rats. Renal failure, 2011, Volume: 33, Issue:10 Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Disease Progression; ErbB Receptors; Gefitinib; Kidney Diseases; Kidney Glomerulus; Male; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; rho-Associated Kinases; Signal Transduction	2011
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Failure	2012
Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model. World journal of gastroenterology, 2011, Nov-28, Volume: 17, Issue:44 Topics: Animals; Cell Line; Cell Proliferation; Colitis; Colon; Colonic Neoplasms; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Trinitrobenzenesulfonic Acid	2011
Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer. Anticancer research, 2011, Volume: 31, Issue:12 Topics: Adult; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Treatment Outcome	2011
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-15, Volume: 18, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays	2012
Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma. Die Pharmazie, 2012, Volume: 67, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aging; Antineoplastic Agents; Disease Progression; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Retrospective Studies; Software; Tomography, X-Ray Computed; Treatment Outcome	2012
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome	2012
Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:3 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome	2012
[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation]. No shinkei geka. Neurological surgery, 2012, Volume: 40, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Ventriculoperitoneal Shunt	2012
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. Molecular oncology, 2012, Volume: 6, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Metabolome; Metabolomics; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome	2012
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Aug-15, Volume: 18, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Recurrence; Risk Factors	2012
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies	2012
The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice. The Journal of endocrinology, 2012, Volume: 214, Issue:3 Topics: Age of Onset; Animals; Diabetes Mellitus, Type 1; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Female; Insulin; Insulin-Secreting Cells; Linagliptin; Mice; Mice, Inbred NOD; Purines; Quinazolines	2012
Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management. The Medical journal of Malaysia, 2012, Volume: 67, Issue:2 Topics: Adenocarcinoma; Adult; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2012
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. Cancer research, 2012, Nov-15, Volume: 72, Issue:22 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Transcription Factors	2012
Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. Journal of medical economics, 2013, Volume: 16, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Health Services; Humans; Lapatinib; Middle Aged; Models, Econometric; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab	2013
Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice. Autoimmunity, 2013, Volume: 46, Issue:1 Topics: Adenine; Animals; Autoimmunity; B-Lymphocytes; Diabetes Mellitus, Type 1; Disease Progression; Female; Flow Cytometry; Histocytochemistry; Insulin-Secreting Cells; Mice; Mice, Inbred NOD; Mice, Transgenic; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Statistics, Nonparametric	2013
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Combined Modality Therapy; Crizotinib; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Young Adult	2012
[Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diarrhea; Disease Progression; ErbB Receptors; Exanthema; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate	2012
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. Reviews on recent clinical trials, 2013, Volume: 8, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic	2013
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 79, Issue:3 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure	2013
Psoriasis aggravation due to lapatinib. BMJ case reports, 2013, Feb-08, Volume: 2013 Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Disease Progression; ErbB Receptors; Female; Humans; Lapatinib; Psoriasis; Quinazolines	2013
Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen. Onkologie, 2002, Volume: 25, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Thiophenes; Treatment Failure	2002
Treatment of advanced gastric cancer: where we are in 2003. Onkologie, 2003, Volume: 26, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Humans; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Thiophenes; Treatment Outcome	2003
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Sep-01, Volume: 9, Issue:10 Pt 1 Topics: Animals; Antineoplastic Agents; Cell Division; Collagen; Collagen Type I; Disease Progression; Electrophoresis, Polyacrylamide Gel; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pheochromocytoma; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Temperature; Time Factors; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein	2003
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis	2004
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Taxoids	2004
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-15, Volume: 10, Issue:2 Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Survival; CSK Tyrosine-Protein Kinase; Cytoskeleton; Disease Progression; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; p21-Activated Kinases; Phenotype; Phosphorylation; Precipitin Tests; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Transfection; Vinculin	2004
Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2004, Volume: 43, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Rate	2004
Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jul-01, Volume: 10, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Quinazolines; Salvage Therapy; Sex Factors; Time Factors; Treatment Outcome	2004
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Time Factors; Treatment Outcome	2004
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 1 Topics: Angiogenesis Inhibitors; Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Melanoma; Mice; Mice, Inbred BALB C; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Oligonucleotides, Antisense; Phenotype; Piperidines; Placebos; Quinazolines; RNA; Transfection; Treatment Outcome; Vascular Endothelial Growth Factor A	2004
Gefitinib (Iressa) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center. Sao Paulo medical journal = Revista paulista de medicina, 2004, May-06, Volume: 122, Issue:3 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines	2004
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS medicine, 2005, Volume: 2, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured	2005
Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-15, Volume: 11, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Quinazolines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome	2005
Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 49, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Time Factors; Treatment Outcome	2005
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 49, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome	2005
Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncology research, 2005, Volume: 15, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleural Effusion; Quinazolines; Recurrence; Retreatment; Time Factors	2005
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; DNA-Binding Proteins; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Immunoblotting; Immunoenzyme Techniques; Membrane Proteins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Prostaglandins E; Pyrazoles; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Sulfonamides; Trans-Activators; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2005
Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. The Journal of urology, 2005, Volume: 174, Issue:4 Pt 2 Topics: Angiogenesis Inhibitors; Animals; Cell Line; Child, Preschool; Collagen; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Injections, Intraperitoneal; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones; Receptor, ErbB-2; Transplantation, Heterologous; Wilms Tumor; WT1 Proteins	2005
Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome	2005
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. British journal of cancer, 2005, Dec-12, Volume: 93, Issue:12 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines; Receptor, ErbB-3; Sex Factors; Survival Analysis	2005
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 51, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome	2006
Transactivation of fetal liver kinase-1/kinase-insert domain-containing receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation. Endocrinology, 2006, Volume: 147, Issue:3 Topics: Atherosclerosis; Benzoquinones; Blotting, Western; Cell Line; Cell Proliferation; Cell Survival; Cells, Cultured; Cinnamates; CSK Tyrosine-Protein Kinase; Disease Progression; Endothelial Cells; Endothelium, Vascular; Humans; Immunoblotting; Immunoprecipitation; Lactams, Macrocyclic; Ligands; Lysophosphatidylcholines; Phosphorylation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinones; Rifabutin; src-Family Kinases; Transcriptional Activation; Transfection; Vascular Endothelial Growth Factor Receptor-2	2006
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer research, 2006, Jan-15, Volume: 66, Issue:2 Topics: Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Lung Neoplasms; Predictive Value of Tests; Prognosis; Quinazolines; Transcription Factors; Transfection; Zinc Finger E-box-Binding Homeobox 1	2006
Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia. BJU international, 2006, Volume: 97, Issue:3 Topics: Adrenergic alpha-Antagonists; Disease Progression; Humans; Male; Prostatic Hyperplasia; Quinazolines; Risk Factors; Urination Disorders	2006
Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma. Respirology (Carlton, Vic.), 2006, Volume: 11, Issue:3 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome	2006
[From ASCO and WCLC 2005 to the clinical practice: targeted therapies]. Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Patient Selection; Placebos; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Time Factors; Vascular Endothelial Growth Factor A	2006
Three-year survival in metastatic non-small cell lung cancer treated with gefitinib. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 53, Issue:1 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Rate; Time Factors	2006
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-01, Volume: 12, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate; Treatment Outcome	2006
Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89, Issue:6 Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2006
Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. Cancer, 2006, Oct-15, Volume: 107, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Risk Factors	2006
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-01, Volume: 12, Issue:19 Topics: Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid	2006
Molecular on/off switch. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-20, Volume: 24, Issue:30 Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Treatment Outcome	2006
[Gefitinib in the treatment of advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome	2006
Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 56, Issue:1 Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2007
Targeted therapy for metastatic breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2	2006
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncology reports, 2007, Volume: 17, Issue:2 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Fluorouracil; Gene Deletion; Genotype; Heterozygote; Humans; Models, Statistical; Mutation; Polymorphism, Genetic; Quinazolines; Sequence Analysis, DNA; Thiophenes; Thymidylate Synthase; Treatment Outcome	2007
[Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer]. Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2006, Volume: 44, Issue:2 Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Quinazolines	2006
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction	2006
Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:1 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2007
The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:5 Topics: Aged; Aneuploidy; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 7; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Logistic Models; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Survival Analysis	2007
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-15, Volume: 13, Issue:10 Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome	2007
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 57, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines	2007
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2007
Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-20, Volume: 25, Issue:27 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Research Design; Vascular Endothelial Growth Factor A	2007
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2008, Volume: 59, Issue:2 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed	2008
Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics. Molecular cancer therapeutics, 2007, Volume: 6, Issue:11 Topics: Animals; Asian People; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Drug Delivery Systems; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Mice; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphotyrosine; Proteomics; Quinazolines; Reproducibility of Results	2007
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. British journal of cancer, 2007, Dec-03, Volume: 97, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2007
Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy. Lung cancer (Amsterdam, Netherlands), 2008, Volume: 60, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cesarean Section; Disease Progression; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Infant, Newborn; Lung Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Quinazolines; Withholding Treatment	2008
[Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Exanthema; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction; Survival Rate	2007
Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. International journal of cancer, 2008, Apr-15, Volume: 122, Issue:8 Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Acinar Cell; Carcinoma, Lobular; Disease Progression; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Mice; Mice, Inbred BALB C; Mice, Transgenic; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction; Up-Regulation	2008
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7 Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2008
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU international, 2008, Volume: 101, Issue:7 Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Erectile Dysfunction; Humans; Male; Nocturia; Patient Satisfaction; Prostatic Hyperplasia; Prostatism; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urinary Retention	2008
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:4 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate	2008
Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:4 Topics: Adenocarcinoma; Aged; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Tomography Scanners, X-Ray Computed; Treatment Failure	2008
Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Apr-15, Volume: 14, Issue:8 Topics: Animals; Azoxymethane; CCAAT-Enhancer-Binding Protein-beta; Colonic Neoplasms; Cyclin D; Cyclins; Disease Progression; ErbB Receptors; Gefitinib; Male; Precancerous Conditions; Quinazolines; Rats; Rats, Inbred F344; STAT3 Transcription Factor; Transcription Factor AP-1	2008
Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression. Carcinogenesis, 2000, Volume: 21, Issue:12 Topics: Amphiregulin; Animals; Betacellulin; Butylhydroxybutylnitrosamine; Carcinogens; Disease Progression; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glycoproteins; Growth Substances; Heparin-binding EGF-like Growth Factor; Intercellular Signaling Peptides and Proteins; Kidney; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic; Tyrphostins	2000
[Non-alcoholic steatohepatitis with cirrhosis after raltitrexed administration]. Gastroenterologie clinique et biologique, 2001, Volume: 25, Issue:2 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Disease Progression; Drug Monitoring; Fat Necrosis; Fatty Liver; Female; Humans; Liver Cirrhosis; Liver Function Tests; Middle Aged; Quinazolines; Rectal Neoplasms; Thiophenes; Thymidylate Synthase	2001
Growth inhibition of prostate cancer xenografts by halofuginone. The Prostate, 2002, May-01, Volume: 51, Issue:2 Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Apoptosis; Collagen Type I; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Phenotype; Piperidines; Prostatic Neoplasms; Quinazolines; Quinazolinones	2002